EurekaMag PDF full texts Chapter 49,905

Hansen, K.; Lançon, C.; Toumi, M. 2006: Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?. European Journal of Health Economics: Hepac: Health Economics in Prevention and Care 7(1): 19-29

Stratchounski, L.S.; Rozenson, O.L. 1999: Pharmacoeconomic perspectives in Russia. Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 2(3): 246-248

Wawruch, M.; Bozeková, L.; Krcméry, S.; Kozlíková, K.; Foltán, V.; Lassánová, M.; Kriska, M. 2005: Pharmacoeconomic profile of antibiotics used in the treatment of lower respiratory tract infections in geriatric patients. Ceska a Slovenska Farmacie: Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti 54(2): 90-95

Postma, M.J. 2003: Pharmacoeconomic research. Pharmacy World and Science: Pws 25(6): 245-246

Bartkó, G.ör.; Fehér, L.ás.ó 2005: Pharmacoeconomic review of the use of injectable long-acting risperidone. Neuropsychopharmacologia Hungarica: a Magyar Pszichofarmakologiai Egyesulet Lapja 7(4): 199-207

Cornago, D.; Li Bassi, L.; De Compadri, P.; Garattini, L. 2007: Pharmacoeconomic studies in Italy: a critical review of the literature. European Journal of Health Economics: Hepac: Health Economics in Prevention and Care 8(2): 89-95

Miravitlles, M.; Jardim, J.R.; Zitto, T.; Rodrigues, J.E.; López, H. 2003: Pharmacoeconomic study of antibiotic therapy for exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Latin America. Archivos de Bronconeumologia 39(12): 549-553

Rapeport, D.; Harper, S.; Flisberg, P. 2005: Pharmacoeconomic viewpoints on volatile anaesthesia--"much ado about nothing?". Anaesthesia and Intensive Care 33(1): 144-145

Rudakova, A.V. 2003: Pharmacoeconomical aspects of the use of angiotensin converting enzyme inhibitors in clinical practice (lisinopril use). Kardiologiia 43(11): 86-92

Ostroumova, O.D.; Mamaev, V.I.; Ishchenko, K.A.; Shorikova, E.G. 2003: Pharmacoeconomical aspects of the use of beta-blockers in hypertension and heart failure. Kardiologiia 43(5): 87-96

Sokolova, O.P. 2006: Pharmacoeconomical grounds for decision on a basic hypnotic for general anesthesia in surgical interventions. Vestnik Khirurgii Imeni I. I. Grekova 165(4): 60-64

Anguita Sánchez, M. 2004: Pharmacoeconomics and cardiovascular disease. Revista Clinica Espanola 204(8): 391-392

Cosler, L.E. 2003: Pharmacoeconomics and considerations for injectable products: focus on colony-stimulating factors. Journal of Managed Care Pharmacy: Jmcp 9(2 Suppl): 4-5

Briggs, A.H.; Levy, A.R. 2006: Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?. Pharmacoeconomics 24(11): 1079-1086

Tatsch, F.F.; Sette, H.; Vianna, D. 2006: Pharmacoeconomics applied to chronic hepatitis C. Brazilian Journal of Infectious Diseases: An Official Publication of the Brazilian Society of Infectious Diseases 10(1): 51-54

Nuijten, M.J. 1999: Pharmacoeconomics in European decision-making. Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 2(5): 319-322

Jones, J.Spencer. 2006: Pharmacoeconomics in South Africa. South African Medical Journal 96(2): 96

Wozakowska-Kapłon, B.; Kempkiewicz, T. 2003: Pharmacoeconomics in cardiovascular disease. Part 1: pharmacoeconomics in coronary heart disease. Polskie Archiwum Medycyny Wewnetrznej 110(5): 1367-1373

Wozakowska-Kapłon, B.; Kempkiewicz, T. 2003: Pharmacoeconomics in cardiovascular disease. Part 2: pharmacoeconomics in congestive heart failure and arterial hypertension. Polskie Archiwum Medycyny Wewnetrznej 110(5): 1375-1378

Czech, M. 2004: Pharmacoeconomics in contemporary medicine. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 16(Suppl 1): 16-19

Postma, M.J.; Boersma, C.; Gansevoort, R.T. 2008: Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 23(4): 1103-1106

Ariano, R.; Berto, P.; Tracci, D.; Incorvaia, C.; Frati, F. 2006: Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy and Asthma Proceedings 27(2): 159-163

Boersma, C.; Atthobari, J.; Gansevoort, R.T.; de Jong-Van den Berg, L.T.W.; de Jong, P.E.; de Zeeuw, D.; Annemans, L.J.P.; Postma, M.J. 2006: Pharmacoeconomics of angiotensin Ii antagonists in type 2 diabetic patients with nephropathy: implications for decision making. Pharmacoeconomics 24(6): 523-535

Szucs, T.D.; Bramkamp, M. 2006: Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. Journal of Thrombosis and Haemostasis: Jth 4(6): 1180-1185

Johnson, M.D.; Kleinberg, M.; Danziger, L.; Ostrosky-Zeichner, L. 2005: Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions. Expert Opinion on PharmacoTherapy 6(15): 2617-2632

Degli Esposti, L.; Di Martino, M.; Saragoni, S.; Sgreccia, A.; Capone, A.; Buda, S.; Esposti, E.D. 2004: Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. Journal of Clinical Hypertension 6(2): 76-84

Jahnz-Rózyk, K.; Targowski, T. 2004: Pharmacoeconomics of asthma. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 16(Suppl 1): 48-49

Cleland, J.; Thomas, M.; Price, D. 2003: Pharmacoeconomics of asthma treatment. Expert Opinion on PharmacoTherapy 4(3): 311-318

Bushnell, C.D.; Matchar, D.B. 2004: Pharmacoeconomics of atrial fibrillation and stroke prevention. American Journal of Managed Care 10(3 Suppl): S66-S71

Jönsson, L. 2003: Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease. Pharmacoeconomics 21(14): 1025-1037

DeRyke, C.A.; Kuti, J.L.; Mansfield, D.; Dana, A.; Nicolau, D.P. 2006: Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 63(8): 750-755

Kusowska, J. 2006: Pharmacoeconomics of dyspesia and peptic ulcer disease. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 20(115): 125-128

Postma, M.J.; Heijnen, M-Louise.A.; Beutels, P.; Jager, J.C. 2003: Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands. Expert Review of Vaccines 2(4): 477-482

Chernin, E.L. 2004: Pharmacoeconomics of inhaled anesthetic agents: considerations for the pharmacist. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 61(Suppl 4): S18-S22

Bennett, C.L.; Calhoun, E.A. 2004: Pharmacoeconomics of liposomal anthracycline therapy. Seminars in Oncology 31(6 Suppl 13: 191-195

Haycox, A. 2005: Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 23(Suppl 1): 3-16

Jones, T.E.; Smith, B.J.; Polasek, J.F. 2004: Pharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin. Expert Opinion on PharmacoTherapy 5(9): 1887-1897

Murthy, A.; Creinin, M.D. 2003: Pharmacoeconomics of medical abortion: a review of cost in the United States, Europe and Asia. Expert Opinion on PharmacoTherapy 4(4): 503-513

Laux, G. 2004: Pharmacoeconomics of modern antidepressives. Pharmazie in Unserer Zeit 33(4): 320-324

Kiess, W.; Böttner, A.; Blüher, S.; Raile, K.; Seidel, B.; Kapellen, T.; Keller, E.; Kratzsch, J.ür. 2003: Pharmacoeconomics of obesity management in childhood and adolescence. Expert Opinion on PharmacoTherapy 4(9): 1471-1477

Bordeleau, L. 2006: Pharmacoeconomics of systemic therapies for lung cancer. Treatments in Respiratory Medicine 5(2): 129-141

Wang, L.; Barrett, J.F. 2006: Pharmacoeconomics of treatment with the newer anti-Gram-positive agents. Expert Opinion on PharmacoTherapy 7(7): 885-897

Karpov, O.I. 2002: Pharmacoeconomics of ulcers: a view from Saint-Petersburg. Eksperimental'naia i Klinicheskaia Gastroenterologiia 5: 79-82; 129

Słominski, J.M.; Kubiak, A. 2004: Pharmacoeconomics of vaccinations in chronic obstructive pulmonary disease. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 16(Suppl 1): 83-85

Curtiss, F.R. 2003: Pharmacoeconomics--determination of the cost-effectiveness of Helicobacter pylori eradication. Journal of Managed Care Pharmacy: Jmcp 9(5): 451

Pedersen, K.M.øl. 2003: Pharmacoeconomics--survey and status. Ugeskrift for Laeger 165(16): 1670-1674

Bootman, J.L.; McGhan, W.F.; Townsend, R.J. 2006: Pharmacoeconomics: historical perspective. Annals of PharmacoTherapy 40(3): 518-519

Gagnon, J.P.; Smith, M.D.; Rindress, D. 1999: Pharmacoeconomics: identifying the issues overview and advisory panel report summary. Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 2(2): 67-72

Luchins, D.J. 2004: Pharmacoeconomics: the new dismal science. Administration and Policy in Mental Health 31(5): 425-427

Motwani, B.; Khayr, W. 2006: Pharmacoenhancement of protease inhibitors. American Journal of Therapeutics 13(1): 57-63

Rachin, A.P.; Iudel'son, I.B. 2005: Pharmacoepidemiological aspects of chronic daily headache. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 105(8): 66-68

Etminan, M. 2004: Pharmacoepidemiology II: the nested case-control study--a novel approach in pharmacoepidemiologic research. PharmacoTherapy 24(9): 1105-1109

Savo, A.; Maiorano, P.M.; Onder, G.; Bernabei, R. 2004: Pharmacoepidemiology and disability in older adults: can medications slow the age-related decline in physical function?. Expert Opinion on PharmacoTherapy 5(2): 407-413

Vitiello, B. 2005: Pharmacoepidemiology and pediatric psychopharmacology research. Journal of Child and Adolescent Psychopharmacology 15(1): 10-11

Chan, K.A.; Hernandez-Diaz, S. 2004: Pharmacoepidemiology and rheumatic disorders. Rheumatic Diseases Clinics of North America 30(4): 835

Verdoux, H.él.èn.; Tournier, M.; Cougnard, A.; Martin, K.; Bégaud, B. 2006: Pharmacoepidemiology of psychotropic medication: utilisation and impact in real-life conditions. Therapie 61(1): 17-22

Fautrel, B. 2004: Pharmacoepidemiology: lessons from real life. Joint Bone Spine 71(3): 175-177

Morf, H.; Moritz, O. 1956: Pharmacoergastric examinations of Bergenia leaves; contribution to the pathology and physiology of dessication. Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft 289(11): 632-650

Rumler, W. 1964: Pharmacogenetic and Undesirable Drug Effects. Medizinische Klinik 59: 1170-1173

Fischer, R.; Griffin, F. 1964: Pharmacogenetic Aspects of Gustation. Arzneimittel-Forschung 14: 673-686

Kirstein-Grossman, I.; Beckmann, J.S..; Lancet, D.; Miller, A. 2002: Pharmacogenetic Development of Personalized Medicine: Multiple Sclerosis Treatment as a Model. Drug News and Perspectives 15(9): 558-567

Rose, C.M.; Marsh, S.; Ameyaw, M.-M.; McLeod, H.L. 2003: Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Methods in Molecular Medicine 85: 225-237

Hasegawa, Y.; Ando, Y.; Ando, M.; Hashimoto, N.; Imaizumi, K.; Shimokata, K. 2006: Pharmacogenetic approach for cancer treatment-tailored medicine in practice. Annals of the new York Academy of Sciences 1086: 223-232

Sayers, I.; Hall, I.P. 2005: Pharmacogenetic approaches in the treatment of asthma. Current Allergy and Asthma Reports 5(2): 101-108

Stoehlmacher, J.; Goekkurt, E.; Lenz, H.Josef. 2003: Pharmacogenetic aspects in treatment of colorectal cancer--an update. Pharmacogenomics 4(6): 767-777

Zhang, Z.; Hou, G.; Zhang, X.; Yao, H.; Sha, W.; Zhang, X. 2003: Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val). Zhonghua Yi Xue Yi Chuan Xue Za Zhi 20(2): 98-102

Breen, D.P.; Marinaki, A.M.; Arenas, M.; Hayes, P.C. 2005: Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 11(7): 826-833

Ando, Y.; Price, D.K.; Dahut, W.L.; Cox, M.C.; Reed, E.; Figg, W.D. 2002: Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biology and Therapy 1(6): 669-673

Hull, C.; Larson, A.; Leachman, S. 2003: Pharmacogenetic candidate genes for melanoma. Pharmacogenomics 4(6): 753-765

Sukhanov, V.A.; Piruzian, L.A. 2004: Pharmacogenetic challenges in the treatment of mental diseases. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 104(8): 83-86

Klees, T.M.; Sheffels, P.; Thummel, K.E.; Kharasch, E.D. 2005: Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology 102(3): 550-556

Warrington, J.S.; Shaw, L.M. 2005: Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy. Expert Opinion on Drug Metabolism and Toxicology 1(3): 487-503

Tan, B.R.; McLeod, H.L. 2005: Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Seminars in Oncology 32(1): 113-119

Rai, A.K. 2002: Pharmacogenetic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis. Social Philosophy and Policy 19(2): 246-270

Judson, R.S.; Salisbury, B.A.; Reed, C.R.; Ackerman, M.J. 2006: Pharmacogenetic issues in thorough QT trials. Molecular Diagnosis and Therapy 10(3): 153-162

Sykiotis, G.P.; Kalliolias, G.D.; Papavassiliou, A.G. 2005: Pharmacogenetic principles in the Hippocratic writings. Journal of Clinical Pharmacology 45(11): 1218-1220

Ruzzo, A.; Graziano, F.; Kawakami, K.; Watanabe, G.; Santini, D.; Catalano, V.; Bisonni, R.; Canestrari, E.; Ficarelli, R.; Menichetti, E.T.; Mari, D.; Testa, E.; Silva, R.; Vincenzi, B.; Giordani, P.; Cascinu, S.; Giustini, L.; Tonini, G.; Magnani, M. 2006: Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24(12): 1883-1891

Relling, M.V.; Yang, W.; Das, S.; Cook, E.H.; Rosner, G.L.; Neel, M.; Howard, S.; Ribeiro, R.; Sandlund, J.T.; Pui, C.-H.; Kaste, S.C. 2004: Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 22(19): 3930-3936

Bosch, T.M.; Doodeman, V.D.; Smits, P.H.M.; Meijerman, I.; Schellens, J.H.M.; Beijnen, J.H. 2006: Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Molecular Diagnosis and Therapy 10(3): 175-185

Bosch, T.M.; Huitema, A.D.R.; Doodeman, V.D.; Jansen, R.; Witteveen, E.; Smit, W.M.; Jansen, R.L.; van Herpen, C.M.; Soesan, M.; Beijnen, J.H.; Schellens, J.H.M. 2006: Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 12(19): 5786-5793

Lane, H.-Y.; Lee, C.-C.; Liu, Y.-C.; Chang, W.-H. 2005: Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics 6(2): 139-149

Rodríguez-Villanueva, J.; Alsar, M.Jesús.; Avendaño, C.; Gómez-Piqueras, C.; García-Alonso, F. 2003: Pharmacogenetic studies: evaluation guidelines for research ethics committees. Study protocol and patient information sheet (II). Medicina Clinica 120(3): 101-107

Kolik, L.G.; Gudasheva, T.A.; Seredenin, S.B. 2003: Pharmacogenetic study of anxiolytic effects of new cholecystokinin receptor antagonists in animals with different levels of emotionality. Bulletin of Experimental Biology and Medicine 135(5): 440-444

Inoue, S.; Hashiguchi, M.; Chiyoda, T.; Sunami, Y.; Tanaka, T.; Mochizuki, M. 2007: Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences. Pharmacogenomics 8(1): 41-47

Marian, A.J. 2005: Pharmacogenetic study of statin therapy and cholesterol reduction. Current Atherosclerosis Reports 7(3): 177-178

Martínez-Sellés, M.; Castillo, I.; Montenegro, P.; Martín, M.ía.L.; Almendral, J.ús.; Sanjurjo, M.ía. 2005: Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation. Revista Espanola de Cardiologia 58(6): 745-748

Corominas, H.; Díaz, C.; Vázquez, G.; Baiget, M. 2002: Pharmacogenetic study of thiopurine S-methyltransferase (TPMT) and thiopurine toxicity. Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva 94(10): 635-636

Netzer, C.; Biller-Andorno, N. 2004: Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics 18(4): 344-360

Jaillon, P. 2006: Pharmacogenetic testing: utility in drug development and in routine clinical practice. Bulletin de l'Academie Nationale de Medecine 190(1): 25-34; Discussion: 34-36

Apud, J.é A.; Weinberger, D.R. 2006: Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs. Neurorx: the Journal of the American Society for Experimental Neurotherapeutics 3(1): 106-116

Morrow, T. 2004: Pharmacogenetic, pharmacogenomic testing rapidly gaining acceptance. Managed Care 13(11): 54-55

Theilade, M.Due. 2005: Pharmacogenetic-assisted drug development. Regulatory aspects from the viewpoint of the Medical Products Agency. Ugeskrift for Laeger 167(20): 2146-2150

Hansen, L.; Andersen, D. 2005: Pharmacogenetic/regulatory aspects seen from the viewpoint of the industry. Ugeskrift for Laeger 167(20): 2160-2164

Padrini, R.; Ferrari, M. 2003: Pharmacogenetics. New England Journal of Medicine 348(20): 2041-2043; Author Reply 2041-2043

David, S.P. 2004: Pharmacogenetics. Primary Care 31(3): 543-559 Ix

Mealey, K.L. 2006: Pharmacogenetics. Veterinary Clinics of North America. Small Animal Practice 36(5): 961

Goedde, H.W.; Schoepf, E. 1964: Pharmacogenetics (Clinical Problems and Biochemicogenetic Bases). Medizinische Klinik 59: 1849-1860

Daudén Tello, E. 2006: Pharmacogenetics I. Concept, history, objectives and areas of study. Actas Dermo-Sifiliograficas 97(10): 623-629

Matthew, J.R.; Constan, E. 1964: Pharmacogenetics in Pre-Ect Medication. American journal of psychiatry 121: 490-491

Brown, A.M. 1965: Pharmacogenetics of the Mouse. Laboratory animal care 15: 111-118

Galley, H.F.; Mahdy, A.; Lowes, D.A. 2005: Pharmacogenetics and anesthesiologists. Pharmacogenomics 6(8): 849-856

Clancy, C.E.; Zhu, Z.I.; Rudy, Y. 2007: Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. American Journal of Physiology. Heart and Circulatory Physiology 292(1): H66-H75

Gage, B.F.; Eby, C.S. 2003: Pharmacogenetics and anticoagulant therapy. Journal of Thrombosis and Thrombolysis 16(1-2): 73-78

Fontana, P.; Reny, J.-L. 2005: Pharmacogenetics and antiplatelet drugs. La Revue de Medecine Interne 26(9): 725-732

Weston, C.F.M. 2004: Pharmacogenetics and cardiovascular disease management. Hospital Medicine 65(10): 594-598

Hisamuddin, I.M.; Wehbi, M.A.; Yang, V.W. 2007: Pharmacogenetics and diseases of the colon. Current Opinion in Gastroenterology 23(1): 60-66

Rahemtulla, T.; Bhopal, R. 2005: Pharmacogenetics and ethnically targeted therapies. Bmj 330(7499): 1036-1037

Kahn, J.D. 2005: Pharmacogenetics and ethnically targeted therapies: racial drugs need to be put in context. Bmj 330(7506): 1508; Author Reply 1508

Kreek, M.J.; Bart, G.; Lilly, C.; LaForge, K.S.; Nielsen, D.A. 2005: Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacological Reviews 57(1): 1-26

Ho, G.-T.; Lees, C.; Satsangi, J. 2004: Pharmacogenetics and inflammatory bowel disease: progress and prospects. Inflammatory Bowel Diseases 10(2): 148-158

Becquemont, L.; Verstuyft, C.él.; Jaillon, P. 2006: Pharmacogenetics and interindividual variability in drug response: cytochrome P-450 2C9 and coumarin anticoagulants. Bulletin de l'Academie Nationale de Medecine 190(1): 37-49; Discussion: 50-53

Hahn, K.K.; Wolff, J.J.; Kolesar, J.M. 2006: Pharmacogenetics and irinotecan therapy. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 63(22): 2211-2217

Liakhovich, V.V.; Vavilin, V.A.; Grishanova, A. I.; Makarova, S.I.; Kovalenko, S.P. 2004: Pharmacogenetics and modern medicine. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk 10: 40-45

Munafò, M.R.; Shields, A.E.; Berrettini, W.H.; Patterson, F.; Lerman, C. 2005: Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics 6(3): 211-223

Marsh, S.; McLeod, H.L. 2007: Pharmacogenetics and oncology treatment for breast cancer. Expert Opinion on PharmacoTherapy 8(2): 119-127

Kalow, W. 2002: Pharmacogenetics and personalised medicine. Fundamental and Clinical Pharmacology 16(5): 337-342

Latif, D.A. 2005: Pharmacogenetics and pharmacogenomics instruction in schools of pharmacy in the USA: is it adequate?. Pharmacogenomics 6(4): 317-319

Schmitz, G.; Schmitz-Madry, A.; Ugocsai, P. 2007: Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Current Opinion in Lipidology 18(2): 164-173

Yan, L.; Davis, H.M. 2006: Pharmacogenetics and pharmacogenomics of therapeutic monoclonal antibodies. Pharmacogenomics 7(7): 961-964

Brand, E. 2003: Pharmacogenetics and pharmacogenomics. Searching for individual antihypertensive therapy concepts. MMW Fortschritte der Medizin 145(19): 43-44

Weinshilboum, R.M.; Wang, L. 2006: Pharmacogenetics and pharmacogenomics: development, science, and translation. Annual Review of Genomics and Human Genetics 7: 223-245

Loni, L.; De Braud, F.; Zinzani, P.Luigi.; Danesi, R. 2003: Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma. Leukemia and Lymphoma 44 Suppl. 3: S115-S122

Basu, A.; Tsapakis, E.; Aitchison, K. 2004: Pharmacogenetics and psychiatry. Current Psychiatry Reports 6(2): 134-142

Melzer, D.; Detmer, D.; Zimmern, R. 2003: Pharmacogenetics and public policy: expert views in Europe and North America. Pharmacogenomics 4(6): 689-691

Muszkat, M.; Stein, C.M. 2005: Pharmacogenetics and response to beta-adrenergic receptor antagonists in heart failure. Clinical Pharmacology and Therapeutics 77(3): 123-126

Asanuma, Y.; Xie, H-Guang.; Stein, C.Michael. 2005: Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response. Arthritis and Rheumatism 52(5): 1349-1359

Andreassen, O.A.; Steen, V.M. 2006: Pharmacogenetics and tailored drug treatment in schizophrenia. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 126(18): 2400-2402

Ling, T.; Raven, A. 2006: Pharmacogenetics and uncertainty: implications for policy makers. Studies in History and Philosophy of Biological and Biomedical Sciences 37(3): 533-549

Wilffert, B.; Zaal, R.; Brouwers, J.R.B.J. 2005: Pharmacogenetics as a tool in the therapy of schizophrenia. Pharmacy World and Science: Pws 27(1): 20-30

Bukaveckas, B.L.; Valdes, R.; Linder, M.W. 2004: Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia. Journal of Cardiothoracic and Vascular Anesthesia 18(3): 353-365

Efferth, T.; Volm, M. 2005: Pharmacogenetics for individualized cancer chemotherapy. Pharmacology and Therapeutics 107(2): 155-176

Ozdemir, V.; Aklillu, E.; Mee, S.; Bertilsson, L.; Albers, L.J.; Graham, J.E.; Caligiuri, M.; Lohr, J.B.; Reist, C. 2006: Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opinion on PharmacoTherapy 7(2): 119-133

Brdicka, R. 2005: Pharmacogenetics from the aspect of the Coordinating Group for Pharmacogenetics of OECD. Casopis Lekaru Ceskych 144(2): 134-135

Kilborn, M. 2001: Pharmacogenetics in Evidence-based practice--what to watch for. Evidence-Based Cardiovascular Medicine 5(4): 109-110

Rodríguez-Nóvoa, S.; Barreiro, P.; Jiménez-Nacher, I.; Rendón, A.; Soriano, V. 2005: Pharmacogenetics in HIV therapy. Aids Reviews 7(2): 103-112

Constable, S.; Johnson, M.R.; Pirmohamed, M. 2006: Pharmacogenetics in clinical practice: considerations for testing. Expert Review of Molecular Diagnostics 6(2): 193-205

Wu, X.; Lu, C.; Chiang, S.S.; Ajani, J.A. 2005: Pharmacogenetics in esophageal cancer. Seminars in Oncology 32(6 Suppl 9: S87-S89

Rogausch, A.; Brockmöller, J.; Himmel, W. 2005: Pharmacogenetics in future medical care -- implications for patients and physicians. Gesundheitswesen 67(4): 257-263

Maitland-van, d.Z.A.-H.; Klungel, O.H.; de Boer, A. 2004: Pharmacogenetics in health-care practice. Pharmacy World and Science: Pws 26(5): 253-255

McNamara, D.M. 2004: Pharmacogenetics in heart failure: genomic markers of endothelial and neurohumoral function. Congestive Heart Failure 10(6): 302-308

Pierik, M.; Rutgeerts, P.; Vlietinck, R.; Vermeire, S. 2006: Pharmacogenetics in inflammatory bowel disease. World Journal of Gastroenterology 12(23): 3657-3667

Nnadi, C.U.; Goldberg, J.F.; Malhotra, A.K. 2005: Pharmacogenetics in mood disorder. Current Opinion in Psychiatry 18(1): 33-39

Depondt, C. 2006: Pharmacogenetics in neuropsychiatric diseases: epilepsy as a model. Acta Neurologica Belgica 106(4): 157-167

Greb, R.R.; Behre, H.M.; Simoni, M. 2005: Pharmacogenetics in ovarian stimulation - current concepts and future options. Reproductive Biomedicine Online 11(5): 589-600

Collier, D.A. 2003: Pharmacogenetics in psychosis. Drug News and Perspectives 16(3): 159-165

Blackhall, F.H.; Howell, S.; Newman, B. 2006: Pharmacogenetics in the management of breast cancer -- prospects for individualised treatment. Familial Cancer 5(2): 151-157

Greaves, M. 2005: Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?. Plos Medicine 2(10): E342

Cronstein, B.N. 2006: Pharmacogenetics in the rheumatic diseases. Bulletin of the Nyu Hospital for Joint Diseases 64(1-2): 16-19

Tellería Orriols, J.J.; Blanco Quirós, A. 2006: Pharmacogenetics in the treatment of asthma. Anales de Pediatria 64(3): 221-223

Burckart, G.J.; Liu, X.I. 2006: Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics?. Therapeutic Drug Monitoring 28(1): 23-30

Altavilla, G.; Marabello, G. 2004: Pharmacogenetics in tumors of the lung. I Suppli di Tumori: Official Journal of Societa Italiana di Cancerologia . 3(2): S31-S32

Sakaeda, T.; Nakamura, T.; Okumura, K. 2003: Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4(4): 397-410

Weinstock-Guttman, B.; Tamaño-Blanco, M.; Bhasi, K.; Zivadinov, R.; Ramanathan, M. 2007: Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology 182(1-2): 236-239

Xiang, X.; Jada, S.Rao.; Li, H.Hua.; Fan, L.; Tham, L.San.; Wong, C.Ing.; Lee, S.Chin.; Lim, R.; Zhou, Q.Yu.; Goh, B.Cher.; Tan, E.Huat.; Chowbay, B. 2006: Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenetics and Genomics 16(9): 683-691

Mehta, P.A.; Davies, S.M. 2004: Pharmacogenetics of acute lymphoblastic leukemia. Current Opinion in Hematology 11(6): 434-438

Knoche, E.; McLeod, H.L.; Graubert, T.A. 2006: Pharmacogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics 7(5): 719-729

Stamer, U.M.; Stuber, F. 2005: Pharmacogenetics of anesthetic and analgesic agents: CYP2D6 genetic variations. Anesthesiology 103(5): 1099; Author Reply 1101

Coto, E.; Marín, R.; Alvarez, V.; Praga, M.; Fernández Andrade, C.; Arias, M.; Poveda, R.; Vallés, M.; Galcerán, J.M.; Luño, J.; Rivera, F.; Campistol, J.M. 2005: Pharmacogenetics of angiotensin system in non diabetic nephropathy. Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 25(4): 381-386

Nguyen, T.V. 2005: Pharmacogenetics of anti-resorptive therapy efficacy: a Bayesian interpretation. Osteoporosis International: a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the Usa 16(8): 857-860

Darbar, D.; Roden, D.M. 2006: Pharmacogenetics of antiarrhythmic therapy. Expert Opinion on PharmacoTherapy 7(12): 1583-1590

Murphy, G.M.; Kremer, C.; Rodrigues, H.E.; Schatzberg, A.F. 2003: Pharmacogenetics of antidepressant medication intolerance. American Journal of Psychiatry 160(10): 1830-1835

Kreutz, R. 2004: Pharmacogenetics of antihypertensive drug response. Current Hypertension Reports 6(1): 15-20

Schwartz, G.L.; Turner, S.T. 2004: Pharmacogenetics of antihypertensive drug responses. American Journal of Pharmacogenomics: Genomics-Related Research in Drug Development and Clinical Practice 4(3): 151-160

Arnett, D.K.; Claas, S.A.; Glasser, S.P. 2006: Pharmacogenetics of antihypertensive treatment. Vascular Pharmacology 44(2): 107-118

Arbouw, M.E.L.; van Vugt, J.P.P.; Egberts, T.C.G.; Guchelaar, H.-J. 2007: Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. Pharmacogenomics 8(2): 159-176

Curtin, R.; Fitzgerald, D.J. 2002: Pharmacogenetics of antiplatelet drugs. Thescientificworldjournal 2: 791-800

Ozaki, N. 2004: Pharmacogenetics of antipsychoatics. Nagoya Journal of Medical Science 67(1-2): 1-7

Lerer, B.; Segman, R.H. 2006: Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. Dialogues in Clinical Neuroscience 8(1): 85-94

Bondy, B.; Spellmann, I. 2007: Pharmacogenetics of antipsychotics: useful for the clinician?. Current Opinion in Psychiatry 20(2): 126-130

Martin, A.M.; Nolan, D.; Gaudieri, S.; Phillips, E.; Mallal, S. 2004: Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Pharmacogenomics 5(6): 643-655

Tàssies, D. 2006: Pharmacogenetics of antithrombotic drugs. Current Pharmaceutical Design 12(19): 2425-2435

Hall, I.P. 2006: Pharmacogenetics of asthma. Chest 130(6): 1873-1878

Mialet-Perez, J.; Liggett, S.B. 2006: Pharmacogenetics of beta1-adrenergic receptors in heart failure and hypertension. Archives des Maladies du Coeur et des Vaisseaux 99(6): 616-620

Taylor, D.R. 2006: Pharmacogenetics of beta2-agonist drugs in asthma. Clinical Reviews in Allergy and Immunology 31(2-3): 247-258

Largillier, R.ém.; Etienne-Grimaldi, M.-C.; Formento, J.-L.; Ciccolini, J.; Nebbia, J.-F.ço.; Ginot, A.él.; Francoual, M.; Renée, N.; Ferrero, J.-M.; Foa, C.; Namer, M.ïs.; Lacarelle, B.; Milano, G.ér. 2006: Pharmacogenetics of capecitabine in advanced breast cancer patients. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 12(18): 5496-5502

Johnson, J.A.; Humma, L.M. 2002: Pharmacogenetics of cardiovascular drugs. Briefings in Functional Genomics and Proteomics 1(1): 66-79

Zineh, I.; Johnson, J.A. 2006: Pharmacogenetics of chronic cardiovascular drugs: applications and implications. Expert Opinion on PharmacoTherapy 7(11): 1417-1427

Vasků, A.; Spinarová, L.; Pávková-Goldbergová, M.; Spinar, J.; Soucek, M.; Vítovec, J. 2006: Pharmacogenetics of chronic heart failure--beta blockers. Casopis Lekaru Ceskych 145(2): 148-152; Discussion: 152-153

Marsh, S. 2005: Pharmacogenetics of colorectal cancer. Expert Opinion on PharmacoTherapy 6(15): 2607-2616

De Castro, F.; Morón, F.J.; Montoro, L.; Real, L.M.; Ruiz, A.ín. 2005: Pharmacogenetics of controlled ovarian hyperstimulation. Pharmacogenomics 6(6): 629-637

Tanaka, E.; Taniguchi, A.; Urano, W.; Yamanaka, H.; Kamatani, N. 2004: Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Practice and Research. Clinical Rheumatology 18(2): 233-247

Scharfetter, J. 2004: Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update. Pharmacogenomics 5(6): 691-698

Sills, G.J. 2005: Pharmacogenetics of epilepsy: one step forward?. Epilepsy Currents 5(6): 236-238

Robien, K.; Boynton, A.; Ulrich, C.M. 2005: Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 6(7): 673-689

Novelli, G.; Margiotti, K.; Chiocca, A.Maria.; Spera, E.; Micali, F.; Reichardt, J.K.V. 2004: Pharmacogenetics of human androgens and prostate cancer--an update. Pharmacogenomics 5(3): 283-294

Sychov, D.A.; Kropacheva, E.S.; Ignat'ev, I.V.; Bulytova, I.M.; Dobrovol'skiĭ, A.B.; Panchenko, E.P.; Kukes, V.G. 2006: Pharmacogenetics of indirect anticoagulants: value of genotype for improvement of efficacy and safety of therapy. Kardiologiia 46(7): 72-77

Kelleher, D.; Farrell, R.; McManus, R. 2004: Pharmacogenetics of inflammatory bowel disease. Novartis Foundation Symposium 263: 41-53; Discussion: 53-56; 211-218

Marsh, S.; McLeod, H.L. 2004: Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 5(7): 835-843

Innocenti, F.; Ratain, M.J. 2006: Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7(8): 1211-1221

Krajinovic, M.; Moghrabi, A. 2004: Pharmacogenetics of methotrexate. Pharmacogenomics 5(7): 819-834

Glatt, C.E.; Reus, V.I. 2003: Pharmacogenetics of monoamine transporters. Pharmacogenomics 4(5): 583-596

Koren, G.; Cairns, J.; Chitayat, D.; Gaedigk, A.; Leeder, S.J. 2006: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368(9536): 704

Haas, D.W.; Bartlett, J.A.; Andersen, J.W.; Sanne, I.; Wilkinson, G.R.; Hinkle, J.; Rousseau, F.; Ingram, C.D.; Shaw, A.; Lederman, M.M.; Kim, R.B. 2006: Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 43(6): 783-786

Swan, G.E.; Benowitz, N.L.; Jacob, P.; Lessov, C.N.; Tyndale, R.F.; Wilhelmsen, K.; Krasnow, R.E.; McElroy, M.R.; Moore, S.E.; Wambach, M. 2004: Pharmacogenetics of nicotine metabolism in twins: methods and procedures. Twin Research: the Official Journal of the International Society for Twin Studies 7(5): 435-448

Mayer, P.; Höllt, V. 2006: Pharmacogenetics of opioid receptors and addiction. Pharmacogenetics and Genomics 16(1): 1-7

Rojas, J.C.és.; Aguilar, B.; Rodríguez-Maldonado, E.; Collados, M.ía.T. 2005: Pharmacogenetics of oral anticoagulants. Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 16(6): 389-398

Spratlin, J.; Sawyer, M.B. 2007: Pharmacogenetics of paclitaxel metabolism. Critical Reviews in Oncology/Hematology 61(3): 222-229

Maitland-van der Zee, A.-H.; Boerwinkle, E. 2005: Pharmacogenetics of response to statins: where do we stand?. Current Atherosclerosis Reports 7(3): 204-208

Reynolds, G.P.; Templeman, L.A.; Godlewska, B.R. 2006: Pharmacogenetics of schizophrenia. Expert Opinion on PharmacoTherapy 7(11): 1429-1440

Serretti, A.; Zanardi, R.; Franchini, L.; Artioli, P.; Dotoli, D.; Pirovano, A.; Smeraldi, E. 2004: Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up. Pharmacogenetics 14(9): 607-613

Toffoli, G.; Cecchin, E. 2003: Pharmacogenetics of stomach cancer. I Suppli di Tumori: Official Journal of Societa Italiana di Cancerologia . 2(5): S19-S22

Goetz, M.P.; Rae, J.M.; Suman, V.J.; Safgren, S.L.; Ames, M.M.; Visscher, D.W.; Reynolds, C.; Couch, F.J.; Lingle, W.L.; Flockhart, D.A.; Desta, Z.; Perez, E.A.; Ingle, J.N. 2005: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23(36): 9312-9318

Lal, S.; Jada, S.R.; Xiang, X.; Lim, W.-T.; Lee, E.J.D.; Chowbay, B. 2006: Pharmacogenetics of target genes across the warfarin pharmacological pathway. Clinical Pharmacokinetics 45(12): 1189-1200

Agema, W.R.P.; Wouter Jukema, J.; de Maat, M.P.M.; Zwinderman, A.H.; Kastelein, J.J.P.; Rabelink, T.J.; van der Wall, E.E. 2004: Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis. Thrombosis and Haemostasis 91(5): 986-990

Daly, A.K. 2004: Pharmacogenetics of the cytochromes P450. Current Topics in Medicinal Chemistry 4(16): 1733-1744

Falkowski, A.; Kaczmarczyk, M.; Goracy, I.; Górecka-Szyld, B.; Poncyljusz, W.; Parczewski, M.ło.; Ciechanowicz, A. 2005: Pharmacogenetics of the local thrombolysis in patients with deep vein thrombosis. Polskie Archiwum Medycyny Wewnetrznej 114(1): 644-651

Ranganathan, P. 2005: Pharmacogenetics of therapies in rheumatoid arthritis. Drugs of Today 41(12): 799-814

Wechsler, M.E.; Israel, E. 2002: Pharmacogenetics of treatment with leukotriene modifiers. Current Opinion in Allergy and Clinical Immunology 2(5): 395-401

Nagar, S.; Blanchard, R.L. 2006: Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metabolism Reviews 38(3): 393-409

Bateman, C. 2005: Pharmacogenetics offers hope. South African Medical Journal 95(1): 19-20

Allorge, D.; Loriot, M.-A. 2004: Pharmacogenetics or the promise of a personalized medicine: variability in drug metabolism and transport. Annales de Biologie Clinique 62(5): 499-511

Hosford, D.A.; Lai, E.H.; Riley, J.H.; Xu, C-Fang.; Danoff, T.M.; Roses, A.D. 2004: Pharmacogenetics to predict drug-related adverse events. Toxicologic Pathology 32 Suppl. 1: 9-12

Kollek, R.; van Aken, J.; Feuerstein, G.; Schmedders, M. 2006: Pharmacogenetics, adverse drug reactions and public health. Community Genetics 9(1): 50-54

Gardiner, S.J.; Begg, E.J. 2006: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacological Reviews 58(3): 521-590

Corrigan, O.P. 2005: Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report. Journal of Medical Ethics 31(3): 144-148

Motulsky, A.G.; Qi, M. 2006: Pharmacogenetics, pharmacogenomics and ecogenetics. Journal of Zhejiang University. Science. B 7(2): 169-170

Herranz, J.L. 2006: Pharmacogenetics, pharmacogenomics and individualised antiepileptic therapy. Revista de Neurologia 43(Suppl 1): S43-S49

Davies, S.M. 2006: Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet?. Hematology. American Society of Hematology. Education Program 2006: 111-117

Terra, S.G.; Johnson, J.A. 2002: Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward. American Journal of Cardiovascular Drugs: Drugs Devices and other Interventions 2(5): 287-296

Mansell, M.A. 2003: Pharmacogenetics, placebos and publication fraud. Medico-Legal Journal 71(Pt 4): 141-143

Jones, D.S.; Perlis, R.H. 2006: Pharmacogenetics, race, and psychiatry: prospects and challenges. Harvard Review of Psychiatry 14(2): 92-108

Clemerson, J.P.; Payne, K.; Bissell, P.; Anderson, C. 2006: Pharmacogenetics, the next challenge for pharmacy?. Pharmacy World and Science: Pws 28(3): 126-130

West, G.B.; Harris, J.M. 1964: Pharmacogenetics--A Fresh Approach to the Problem of Allergy. Annals of the New York Academy of Sciences 118: 441-452

Nahum, L.H. 1964: Pharmacogenetics--A new Discipline. Connecticut medicine 28: 857-858

Tucker, G. 2004: Pharmacogenetics--expectations and reality. Bmj 329(7456): 4-6

Dzida, G. 2004: Pharmacogenetics--new perspectives in the treatment of cardiovascular diseases. Kardiologia Polska 60(3): 304-308

Ainsworth, M.A.; Nielsen, O.H. 2005: Pharmacogenetics--new therapeutic possibilities. Ugeskrift for Laeger 167(20): 2141

Kurland, L.; Lind, L.; Lithell, H.; Syvänen, A.-C.; Melhus, H.åk. 2003: Pharmacogenetics--pathway to individualized antihypertensive pharmacotherapy. Lakartidningen 100(8): 600-603

Kurth, J.H. 2003: Pharmacogenetics--the horizon. Reviews in Gastroenterological Disorders 3(Suppl 1): S3-S8

Kola, I. 2005: Pharmacogenetics--where are we and where are we heading?. Pharmacogenomics 6(8): 793-795

Clarke, C.A. 1962: Pharmacogenetics-a study of inherited variability in the response to drugs. Journal of Pharmacy and Pharmacology 14(Suppl): 20t-30t

Gage, B.F. 2006: Pharmacogenetics-based coumarin therapy. HEMATOLOGY. American Society of Hematology. Education Program 2006: 467-473

Roots, I.; Gerloff, T.; Meisel, C.; Kirchheiner, J.; Goldammer, M.; Kaiser, R.; Laschinski, G.; Brockmöller, J.ür.; Cascorbi, I.; Kleeberg, U.; Hildebrandt, A.G. 2004: Pharmacogenetics-based new therapeutic concepts. Drug Metabolism Reviews 36(3-4): 617-638

Scharplatz, M.; Puhan, M.; Steurer, J.; Bachmann, L.M. 2004: Pharmacogenetics. Tailored therapy in medicine -- opportunities and challenges. Praxis 93(10): 359-365

Huang, Y. 2007: Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Reviews 26(1): 183-201

Ferraccioli, G.; De Santis, M.; Tolusso, B. 2004: Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology. Pharmacogenomics 5(8): 1107-1116

Sookoian, S.; Pirola, C.J. 2004: Pharmacogenetics/pharmacogenomics in clinical practice. Medicina 64(6): 563-567

Merk, H.F. 2005: Pharmacogenetics: Important aspects for dermatology. Der Hautarzt; Zeitschrift für Dermatologie Venerologie und verwandte Gebiete 56(1): 44-47

Nolan, D.; Gaudieri, S.; Mallal, S. 2003: Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?. Journal of HIV Therapy 8(2): 36-41

Adley, K.E.; Keim, M.; Williams, R.S.B. 2006: Pharmacogenetics: defining the genetic basis of drug action and inositol trisphosphate analysis. Methods in Molecular Biology 346: 517-534

Arnold, H.Peter.; McHale, D. 2006: Pharmacogenetics: development issues and solutions for safe and effective medicines. Pharmacogenomics 7(2): 149-155

Sutrop, M. 2004: Pharmacogenetics: ethical issues. Bioethics 18(4): Iii-Viii

Lindpaintner, K. 2003: Pharmacogenetics: forerunner for individualized medicine. Therapeutische Umschau. Revue Therapeutique 60(8): 487-492

Landau, R. 2005: Pharmacogenetics: implications for obstetric anesthesia. International Journal of Obstetric Anesthesia 14(4): 316-323

Weinshilboum, R.; Wang, L. 2004: Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity. Clinical Pharmacology and Therapeutics 75(4): 253-258

Dowling, P. 2006: Pharmacogenetics: it's not just about ivermectin in collies. Canadian Veterinary Journal 47(12): 1165-1168

Woodcock, J. 2005: Pharmacogenetics: on the road to 'personalized medicine'. Fda Consumer 39(6): 44

Corrigan, O.P.; Williams-Jones, B. 2006: Pharmacogenetics: the bioethical problem of DNA investment banking. Studies in History and Philosophy of Biological and Biomedical Sciences 37(3): 550-565

Holgate, S.T. 2004: Pharmacogenetics: the new science of personalizing treatment. Current Opinion in Allergy and Clinical Immunology 4(1): 37-38

Ferriols Lisart, F.; Ferriols Lisart, R. 2003: Pharmacogenetics: where are we and where are we going to?. Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 27(2): 109-120

Polonio, P. 1961: Pharmacogenic disease in psychiatry. British Medical Journal 2(5264): 1425-1427

McLean, L.A.; Gathmann, I.; Capdeville, R.; Polymeropoulos, M.H.; Dressman, M. 2004: Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 10(1 Part 1): 155-165

Smit, M.J.; Vischer, H.F.; Bakker, R.A.; Jongejan, A.; Timmerman, H.; Pardo, L.; Leurs, R. 2007: Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annual Review of Pharmacology and Toxicology 47: 53-87

Hasegawa, Y. 2003: Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(3): 325-333

Impicciatore, M. 2003: Pharmacogenomic can give children safer medicines. Archives of Disease in Childhood 88(4): 366

Yagil, Y.; Yagil, C. 2003: Pharmacogenomic considerations for immunosuppressive therapy. Pharmacogenomics 4(3): 309-319

Attar, M.; Lee, V.H.L. 2003: Pharmacogenomic considerations in drug delivery. Pharmacogenomics 4(4): 443-461

Petrovic, D.; Peterlin, B. 2004: Pharmacogenomic considerations of the insertion/deletion gene polymorphism of the angiotensin I-converting enzyme and coronary artery disease. Current Vascular Pharmacology 2(3): 271-279

Yamazaki, H. 2005: Pharmacogenomic data for personalized medicines. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(12): 1886-1890

Joly, Y.; Knoppers, B.M. 2006: Pharmacogenomic data sample collection and storage: ethical issues and policy approaches. Pharmacogenomics 7(2): 219-226

Trepicchio, W.L.; Williams, G.A.; Essayan, D.; Hall, S.T.; Harty, L.C.; Shaw, P.M.; Spear, B.B.; Wang, S.J.; Watson, M.L. 2004: Pharmacogenomic data submissions to the FDA: clinical case studies. Pharmacogenomics 5(5): 519-524

Ruaño, G.; Collins, J.M.; Dorner, A.J.; Wang, S.-J.; Guerciolini, R.; Huang, S.-M. 2004: Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies. Pharmacogenomics 5(5): 513-517

Leighton, J.K.; DeGeorge, J.; Jacobson-Kram, D.; MacGregor, J.; Mendrick, D.; Worobec, A. 2004: Pharmacogenomic data submissions to the FDA: non-clinical case studies. Pharmacogenomics 5(5): 507-511

Salerno, R.A.; Lesko, L.J. 2004: Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 5(5): 503-505

Walgren, R.A.; Meucci, M.A.; McLeod, H.L. 2005: Pharmacogenomic discovery approaches: will the real genes please stand up?. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23(29): 7342-7349

Wiwanitkit, V. 2006: Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations. Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 12(2): 219-222

Hess, K.R.; Anderson, K.; Symmans, W.F.; Valero, V.; Ibrahim, N.; Mejia, J.A.; Booser, D.; Theriault, R.L.; Buzdar, A.U.; Dempsey, P.J.; Rouzier, R.; Sneige, N.; Ross, J.S.; Vidaurre, T.; Gómez, H.L.; Hortobagyi, G.N.; Pusztai, L. 2006: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24(26): 4236-4244

Issa, A.M. 2003: Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges. Pharmacogenomics 4(5): 647-655

Almon, R.R.; Dubois, D.C.; Jin, J.Y.; Jusko, W.J. 2005: Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series. Aaps Journal 7(1): E156-E194

Ziebuhr, W.; Xiao, K.; Coulibaly, B.; Schwarz, R.; Dandekar, T. 2004: Pharmacogenomic strategies against resistance development in microbial infections. Pharmacogenomics 5(4): 361-379

Pandhi, P. 2006: Pharmacogenomic studies: hype and reality. Indian Journal of Medical Research 123(5): 597-600

Patowary, S. 2005: Pharmacogenomics - therapeutic and ethical issues. Kathmandu University Medical Journal 3(4): 428-430

Arnold, H.P.; Hall, S.T. 2005: Pharmacogenomics and Clinical R&D. Pharmacogenomics 6(8): 801-806

Haas, D.W. 2005: Pharmacogenomics and HIV therapeutics. Journal of Infectious Diseases 191(9): 1397-1400

Sandborn, W.J. 2004: Pharmacogenomics and IBD: TPMT and thiopurines. Inflammatory Bowel Diseases 10(Suppl 1): S35-S37

Aerssens, J.; Paulussen, A.ée.D.C. 2005: Pharmacogenomics and acquired long QT syndrome. Pharmacogenomics 6(3): 259-270

Lymberis, S.C.; Parhar, P.K.; Katsoulakis, E.; Formenti, S.C. 2004: Pharmacogenomics and breast cancer. Pharmacogenomics 5(1): 31-55

Ross, J.S.; Symmans, W.Fraser.; Pusztai, L.; Hortobagyi, G.N. 2005: Pharmacogenomics and clinical biomarkers in drug discovery and development. American Journal of Clinical Pathology 124 Suppl: S29-S41

Iqbal, O. 2004: Pharmacogenomics and coagulation disorders. Methods in Molecular Medicine 93: 253-266

Lenz, H.-J. 2006: Pharmacogenomics and colorectal cancer. Advances in Experimental Medicine and Biology 587: 211-231

Camilleri, M. 2005: Pharmacogenomics and functional gastrointestinal disorders. Pharmacogenomics 6(5): 491-501

Yamada, M. 2002: Pharmacogenomics and future antidepressant research. Seishin Shinkeigaku Zasshi 104(10): 810-818

Yamada, M.; Yamada, M.; Takahashi, K.; Maruyama, Y. 2006: Pharmacogenomics and future development of novel antidepressants. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 128(1): 19-22

Rosell, R.; Cobo, M.; Isla, D.; Camps, C.; Massuti, B. 2006: Pharmacogenomics and gemcitabine. Annals of Oncology: Official Journal of the European Society for Medical Oncology 17 Suppl. 5: V13-V16

Kassack, M.U. 2003: Pharmacogenomics and gene expression analysis. Functional genome research for individual application to patients. Medizinische Monatsschrift für Pharmazeuten 26(5): 165-166

Iyengar, S.; Abraham, W.T. 2004: Pharmacogenomics and heart failure: tailor-made therapy?. Congestive Heart Failure 10(6): 273; 288

Eichelbaum, M.; Ingelman-Sundberg, M.; Evans, W.E. 2006: Pharmacogenomics and individualized drug therapy. Annual Review of Medicine 57: 119-137

White, R.M.; Wong, S.H.Y. 2005: Pharmacogenomics and its applications. Mlo: Medical Laboratory Observer 37(3): 20-27

Regnstrom, K.; Burgess, D.J. 2005: Pharmacogenomics and its potential impact on drug and formulation development. Critical Reviews in Therapeutic Drug Carrier Systems 22(5): 465-492

Manunta, P.; Bianchi, G. 2006: Pharmacogenomics and pharmacogenetics of hypertension: update and perspectives--the adducin paradigm. Journal of the American Society of Nephrology: Jasn 17(4 Suppl 2): S30-S35

Ito, R.K.; Demers, L.M. 2004: Pharmacogenomics and pharmacogenetics: future role of molecular diagnostics in the clinical diagnostic laboratory. Clinical Chemistry 50(9): 1526-1527

Toffoli, G.; Cecchin, E. 2004: Pharmacogenomics and stomach cancer. Pharmacogenomics 5(6): 627-641

Penny, M.A.; McHale, D. 2005: Pharmacogenomics and the drug discovery pipeline: when should it be implemented?. American Journal of Pharmacogenomics: Genomics-Related Research in Drug Development and Clinical Practice 5(1): 53-62

Bala, M.V.; Zarkin, G.A. 2004: Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?. Pharmacoeconomics 22(8): 495-498

Hines, R.N.; McCarver, D.G. 2006: Pharmacogenomics and the future of drug therapy. Pediatric Clinics of North America 53(4): 591-619

Wittkowsky, A.K. 2004: Pharmacogenomics and the management of oral anticoagulation. Current Hematology Reports 3(5): 363-367

Cacabelos, R.ón. 2005: Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Expert Opinion on PharmacoTherapy 6(12): 1967-1987

Frassetto, L.A.; Benet, L.Z. 2004: Pharmacogenomics and transplantation: where are we?. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 4(6): 843

Nebert, D.W.; Jorge-Nebert, L.; Vesell, E.S. 2003: Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. American Journal of Pharmacogenomics: Genomics-Related Research in Drug Development and Clinical Practice 3(6): 361-370

Petsko, G.A. 2004: Pharmacogenomics arrives. Genome Biology 5(6): 108

Wong, S.H.; Wagner, M.A.; Jentzen, J.M.; Schur, C.; Bjerke, J.; Gock, S.B.; Chang, C.-C. 2003: Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity?. Journal of Forensic Sciences 48(6): 1406-1415

Jin, M.; Gock, S.B.; Jannetto, P.J.; Jentzen, J.M.; Wong, S.H. 2005: Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. Journal of Analytical Toxicology 29(7): 590-598

Komamura, K. 2006: Pharmacogenomics for cardiovascular drugs. Nihon Rinsho. Japanese Journal of Clinical Medicine 64(Suppl 5): 465-470

Kupiec, T.C.; Raj, V.; Vu, N. 2006: Pharmacogenomics for the forensic toxicologist. Journal of Analytical Toxicology 30(2): 65-72

Tamaoki, M.; Gushima, H.; Tsutani, K. 2004: Pharmacogenomics in Asia. Pharmacogenomics 5(8): 1023-1027

Salerno, R.A.; Lesko, L.J. 2004: Pharmacogenomics in Drug Development and Regulatory Decision-making: the Genomic Data Submission (GDS) Proposal. Pharmacogenomics 5(1): 25-30

Wajapeyee, N.; Somasundaram, K. 2004: Pharmacogenomics in breast cancer: current trends and future directions. Current Opinion in Molecular Therapeutics 6(3): 296-301

Ansari, M.; Krajinovic, M. 2007: Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. Current Opinion in Pediatrics 19(1): 15-22

Mango, R.; Vecchione, L.; Raso, B.; Borgiani, P.; Brunetti, E.; Mehta, J.L.; Lauro, R.; Romeo, F.; Novelli, G. 2005: Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy. Expert Opinion on PharmacoTherapy 6(15): 2565-2576

Shimizu, C.; Fujiwara, Y. 2006: Pharmacogenomics in chemotherapy and drug development for breast cancer. Nihon Rinsho. Japanese Journal of Clinical Medicine 64(3): 424-431

Bondy, B. 2005: Pharmacogenomics in depression and antidepressants. Dialogues in Clinical Neuroscience 7(3): 223-230

Harr, T.; Itin, P.H. 2005: Pharmacogenomics in dermatology. Journal der Deutschen Dermatologischen Gesellschaft 3(3): 214-221; Quiz 222, 224

Brain, N.; Dominiczak, A.F. 2005: Pharmacogenomics in hypertension: present practicalities and future potential. Journal of Hypertension 23(7): 1327-1329

Egan, L.J.; Derijks, L.J.J.; Hommes, D.W. 2006: Pharmacogenomics in inflammatory bowel disease. Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association 4(1): 21-28

McAlister, V. 2003: Pharmacogenomics in liver transplantation. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 9(10): 1114-1115

García-Campelo, R.; Alonso-Curbera, G.; Antón Aparicio, L.M.; Rosell, R. 2005: Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. Expert Opinion on PharmacoTherapy 6(12): 2015-2026

Riese-Jorda, H.H.; Baez, J.M. 2006: Pharmacogenomics in neuro-oncology. Revista de Neurologia 43(6): 353-356

Anonymous 2004: Pharmacogenomics in psychiatry. Harvard Mental Health Letter 20(7): 4-5

Clancy, C.E.; Kass, R.S. 2003: Pharmacogenomics in the treatment of epilepsy. Pharmacogenomics 4(6): 747-751

Ast, O.; Lüke, W. 2004: Pharmacogenomics of HIV. Current Opinion in Molecular Therapeutics 6(3): 302-307

Jamroziak, K.; Robak, T. 2004: Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 9(2): 91-105

Enoch, M.-A. 2003: Pharmacogenomics of alcohol response and addiction. American Journal of Pharmacogenomics: Genomics-Related Research in Drug Development and Clinical Practice 3(4): 217-232

Taniguchi, A.; Urano, W.; Tanaka, E.; Kamatani, N. 2007: Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis. Nihon Rinsho. Japanese Journal of Clinical Medicine 65(2): 371-379

Pahl, A.; Benediktus, E.; Chialda, L. 2006: Pharmacogenomics of asthma. Current Pharmaceutical Design 12(25): 3195-3206

Baker, D.E. 2003: Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy. Reviews in Gastroenterological Disorders 3(3): 150-157

Bhatnagar, P.; Guleria, R.; Kukreti, R. 2006: Pharmacogenomics of beta2-agonist: key focus on signaling pathways. Pharmacogenomics 7(6): 919-933

Miller, C.R.; McLeod, H.L. 2007: Pharmacogenomics of cancer chemotherapy-induced toxicity. Journal of Supportive Oncology 5(1): 9-14

Tanaka, T.; Oka, T.; Iwao, H. 2006: Pharmacogenomics of cardiovascular pharmacology. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 128(3): 130-132

Pollard, H.B.; Eidelman, O.; Jacobson, K.A.; Srivastava, M. 2001: Pharmacogenomics of cystic fibrosis. Molecular Interventions 1(1): 54-63

Vormfelde, S.V.; Burckhardt, G.; Zirk, A.; Wojnowski, L.; Brockmöller, J.ür. 2003: Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. Pharmacogenomics 4(6): 701-734

Filigheddu, F.; Troffa, C.; Glorioso, N. 2006: Pharmacogenomics of essential hypertension: are we going the right way?. Cardiovascular and Hematological Agents in Medicinal Chemistry 4(1): 7-15

Lentz, F.; Tran, Aès.; Rey, E.; Pons, Gérard.; Tréluyer, J-Marc. 2005: Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. American Journal of Pharmacogenomics: Genomics-Related Research in Drug Development and Clinical Practice 5(1): 21-33

Fredericks, S.; Holt, D.W. 2003: Pharmacogenomics of immunosuppressive drug metabolism. Current Opinion in Nephrology and Hypertension 12(6): 607-613

Schillaci, G. 2004: Pharmacogenomics of left ventricular hypertrophy reversal: beyond the 'one size fits all' approach to antihypertensive therapy. Journal of Hypertension 22(12): 2273-2275

Yan, Q. 2003: Pharmacogenomics of membrane transporters an overview. Methods in Molecular Biology 227: 1-20

Pinsonneault, J.; Sadée, W. 2003: Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome. Aaps Pharmsci 5(4): E29

Bianchi, G.; Staessen, J.A.; Patrizia, F. 2003: Pharmacogenomics of primary hypertension--the lessons from the past to look toward the future. Pharmacogenomics 4(3): 279-296

Furuta, T.; Shirai, N.; Sugimoto, M.; Ohashi, K.; Ishizaki, T. 2004: Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5(2): 181-202

Pickar, D. 2003: Pharmacogenomics of psychiatric drug treatment. Psychiatric Clinics of North America 26(2): 303

Li, L.; Xie, Y.-c.; Lu, G.-p. 2006: Pharmacogenomics of statin therapy. Zhonghua Xin Xue Guan Bing Za Zhi 34(1): 88-91

Marzolini, C.; Tirona, R.G.; Kim, R.B. 2004: Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5(3): 273-282

Bougnères, P. 2004: Pharmacogenomics of the growth hormone: polymorphism of the receptor in the front line. Medecine Sciences: M/S 20(11): 964-965

Ranganathan, P. 2005: Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 6(5): 481-490

Katoh, M.; Katoh, M. 2004: Pharmacogenomics on gastric cancer. Cancer Biology and Therapy 3(6): 566-567

Traynor, K. 2006: Pharmacogenomics technique predicts chemotherapy success. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 63(23): 2304-2306

Winkelmann, B.R. 2003: Pharmacogenomics, genetic testing and ethnic variability: tackling the ethical questions. Pharmacogenomics 4(5): 531-535

Meurer, M.J. 2003: Pharmacogenomics, genetic tests, and patent-based incentives. Advances in Genetics 50: 399-426; Discussion: 507-510

Preskorn, S.H. 2006: Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future. Journal of Psychopharmacology 20(4 Suppl): 85-94

Dubey, A.K.; Palaian, P.S.; Shankar, P.R. 2006: Pharmacogenomics--a new approach towards personalized medicine. JPMA. Journal of the Pakistan Medical Association 56(9): 426

Bolonna, A.A.; Arranz, M.J.; Mancama, D.; Kerwin, R.W. 2004: Pharmacogenomics--can genetics help in the care of psychiatric patients?. International Review of Psychiatry 16(4): 311-319

Sutphin, S.D.; Smith, K.M. 2005: Pharmacogenomics-Potential applications to orthopedic practice. Orthopedics 28(10): 1157-1159

Couzin, J. 2004: Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim. Science 305(5688): 1222-1223

Wu, E.-T.; Huang, S.-C.; Chiu, I.-S.; Ko, W.-J. 2006: Abdominal compartment syndrome caused failure of venous return in a neonate during extracorporeal membrane oxygenation support. Pediatric Critical Care Medicine: a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 7(4): 400-401

Kaiser, J. 2003: Pharmacogenomics. FDA puts the brakes on Roche's gene array test. Science 302(5648): 1134

Service, R.F. 2005: Pharmacogenomics. Going from genome to pill. Science 308(5730): 1858-1860

Krüth, P.; Wehling, M. 2003: Pharmacogenomics. what is relevant for the internal medicine specialist?. Der Internist 44(12): 1524-1530

Hernandez-Boussard, T.; Klein, T.E.; Altman, R.B. 2006: Pharmacogenomics: the relevance of emerging genotyping technologies. Mlo: Medical Laboratory Observer 38(3): 24; 26-30

Gupta, S.; Jain, S.; Brahmachari, S.K.; Kukreti, R. 2006: Pharmacogenomics: a path to predictive medicine for schizophrenia. Pharmacogenomics 7(1): 31-47

Bepler, G. 2006: Pharmacogenomics: a reality or still a promise?. Lung Cancer 54(Suppl 2): S3-S7

Grimaldi, B.A. 2007: Pharmacogenomics: an assessment of market conditions and competition. Findings Brief: Health Care Financing and Organization 10(3): 1-4

Borchardt, P.E. 2006: Pharmacogenomics: an in-house advantage?. Drug Discovery Today 11(1-2): 1-3

Ishikawa, T. 2005: Pharmacogenomics: current status and future prospectives. Nihon Rinsho. Japanese Journal of Clinical Medicine 63(Suppl 12): 50-56

Sadée, W. 2005: Pharmacogenomics: harbinger for the era of personalized medicine?. Molecular Interventions 5(3): 140-143

Brock, T.P.; Valgus, J.M.; Smith, S.R.; Summers, K.M. 2003: Pharmacogenomics: implications and considerations for pharmacists. Pharmacogenomics 4(3): 321-330

Mahlknecht, U.; Voelter-Mahlknecht, S. 2005: Pharmacogenomics: questions and concerns. Current Medical Research and Opinion 21(7): 1041-1047

Loriot, M.-A.; Beaune, P. 2004: Pharmacogenomics: the link between genes and response to drugs. Medecine Sciences: M/S 20(6-7): 634-636

López-López, M.; Guerrero-Camacho, J.L.; Familiar-López, I.M.; Jung-Cook, H.; Corona-Vázquez, T.; Alonso-Vilatela, M.E. 2004: Pharmacogenomics: the quest for individualized therapy. Revista de Neurologia 39(11): 1063-1071

Mangaldzhiev, N. 1963: Pharmacognosic Studies on Sedum Rhodiola Dc. Nauchni Trudove Na Visshiia Meditsinski Institut Sofiia 42: 15-22

Gheorghiu, A.; Ionescu-Matiu, E.; Manuchian, M. 1964: Pharmacognosic Study of Cytisus Austriacus L. Annales Pharmaceutiques Francaises 22: 137-146

Depasquale, A. 1963: Pharmacognostic Research on the Roots of Coloquintide. Archivio italiano di scienze farmacologiche 13: 174-175

San Martin Casamada, R. 1951: Pharmacognostic examination of powders from cardiotonic drugs from plants. Farmacognosia; Anales del Instituto Jose Celestino Mutis 11(22): 369-373

Kucera, M. 1956: Pharmacognostic examination of the prochamazulenogen containing plants Achillea millefolium L. and Artemisia absinthium L. Die Pharmazie 11(9): 604-609

Lin, X.; Huang, Q.; Li, J.; Mo, G.; Lin, J.; Huang, R. 2005: Pharmacognostic identification of dried twigs and leaves of Taraphochlamys affinis (Giff) Bremekhu. Zhong Yao Cai 28(7): 541-543

Chen, J.-c.; Chen, X.-d. 2002: Pharmacognostic identification of medicinal Asteropyrum plants in China. Zhongguo Zhong Yao Za Zhi 27(2): 94-97

San Martin Casamada, R. 1952: Pharmacognostic notes on Mohammedan drugs. Anales de la Real Academia de Farmacia 18(3): 235-242

Negro, G. 1955: Pharmacognostic observations on Cinnamomum Zeylanicum Cortex. Giornale di Batteriologia E Immunologia 48(5-6): 246-252

Lukic, P.B. 1954: Pharmacognostic part of the new Yugoslav pharmacopeia. Arhiv Za Farmaciju 4(2-3): 62-73

Gherase, Fţa.; Spac, A.; Dorneanu, V.; Stănescu, U.; Grigorescu, E. 2003: Pharmacognostic research of some species of Achillea. Note 1. Volatile oils analysis. Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 107(1): 188-191

Ye, C.-j.; Sun, Y.-z.; Chen, K.-l. 2006: Pharmacognostic studies on Begonia sinensis rhizome. Zhong Yao Cai 29(5): 435-436

Scwar, C. 1955: Pharmacognostic studies on Euphorbia peplus L. Die Pharmazie 10(7): 429-432

Datta, S.C.; Datta, D.; Mukerji, B. 1961: Pharmacognostic studies on leaves of Myrtus communis Linn.--the Indian Buchu of commerce. Journal of Scientific and Industrial Research. C Biological Sciences 20c: 88-91

Xie, L.-S.; Liao, Y.-K.; Huang, Q.-F.; Huang, M.-C. 2005: Pharmacognostic studies on mangrove Acanthus ilicifolius. Zhongguo Zhong Yao Za Zhi 30(19): 1501-1503

Kosova, V.; Chladek, M. 1957: Pharmacognostic study of Datura metel L. and Datura innoxia Mill. Die Pharmazie 12(9): 620-627

Shah, C.S.; Sukkawala, V.M.; Chavan, A.R. 1962: Pharmacognostic study of Merremia emarginata Hallier and comparison with Centella asiatica Linn. Journal of Scientific and Industrial Research. C Biological Sciences 21c: 22-26

Atal, C.K.; Khanna, K.L. 1960: Pharmacognostic study of Valeriana pyrolaefolia Decaisne. Journal of Pharmacy and Pharmacology 12: 739-743

Kraus, L.; Nadherny, J. 1956: Pharmacognostic-anatomic study of the leaf of the sub-family Saniculoidea of Umbelliferae. Die Pharmazie 11(6): 416-419

Fu, K.C.; Hsu, S.K.; Wu, R.H.; Kao, K.B. 1964: Pharmacognostical Studies on the Chinese Drug Ci-Lao-Yia--The Bark of Aralia Mandshurica Rupr. Et Maxim. Yao Xue Xue Bao 11: 824-833

Li, C.; Wu, B.; Yang, J. 2000: Pharmacognostical identification of Phyllanthus niruni. Zhong Yao Cai 23(9): 522-523

Zhou, R.; Luo, Y. 2001: Pharmacognostical identification of Polygonum perfoliatum. Zhong Yao Cai 24(4): 251-254

Cai, Y.; Zhu, Y.-l.; Liu, D.; Teng, J.-b.; Wang, J.-s. 2006: Pharmacognostical identification of Vernonia patula (Dry) Merr. Zhong Yao Cai 29(2): 116-118

Zhong, G.-y.; Xu, L.-s.; Xu, G.-j.; Namba, T. 2002: Pharmacognostical identification of "guijiu ([symbol: see text])" in Shosoin of Japan. Zhongguo Zhong Yao Za Zhi 27(2): 89-94

Prasad, S.; Bhattacharya, I.C. 1961: Pharmacognostical studies on Achyranthes aspera Linn. Journal of Scientific and Industrial Research. C Biological Sciences 20c: 246-251

Tong, W.; Wang, B.-r.; Ai, T.-m. 2003: Pharmacognostical studies on Dactylicapnos scandens. Zhongguo Zhong Yao Za Zhi 28(5): 405-409

Qiao, C.; Xu, L.; Wang, Z. 2001: Pharmacognostical studies on the rhizome, root and leaf of Alpinia jianganfeng T.L. Wu. Zhong Yao Cai 24(3): 165-167

Qiao, C.; Xu, L.; Wang, Z. 2001: Pharmacognostical studies on the root and rhizome of Globba racemosa. Zhong Yao Cai 24(4): 249-250

Hata, K.; Kozawa, M. 1961: Pharmacognostical studies on umbelliferous plants. XVIII. on the constituents of the roots of Angelica Keiskei Koidzumi. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 81: 1647-1649

Hata, K.; Kozawa, M.; Yen, K.Y.; Kimura, Y. 1963: Pharmacognostical studies on umbelliferous plants. XX. Studies on Chinese drug "bvaku-shi". 5. on the coumarins of the roots of Angelica formosana Boiss. and A. anomala Lall. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 83: 611-614

Simonian, V.H.; Youngken, H.W. 1953: Pharmacognostical study of American berberis. Journal of the American Pharmaceutical Association. American Pharmaceutical Association 42(2): 111-116

Beltrami, L. 1958: Pharmacognosty findings on several species of American species of Rauwolfia. Archivio Italiano di Scienze Farmacologiche 8(3): 246-251

Chernykh, N.A.; Zoz, I.G. 1964: Pharmacognosy of Convallaria. Farmatsevtychnyi zhurnal 19: 71-73

Blazek, Z.; Stary, F. 1964: Pharmacognosy of Folium Vincae Minoris. Iii. Total Alkaloid Content and Normalization of the Purity and Quality of the Drugs. Ceskoslovenska farmacie 13: 315-321

Blazek, Z.; Stary, F. 1964: Pharmacognosy of Vinca Minor Leaves. I. Identification of the Drug. Ceskoslovenska farmacie 13: 153-165

Blazek, Z.; Stary, F. 1964: Pharmacognosy of Vinca Minor Leaves. Ii. Comparative Study of the Leaves of some other Species of Vinca and Catharanthus. Ceskoslovenska farmacie 13: 165-172

Efferth, T. 2006: Pharmacognosy and molecular pharmacology of small molecules of natural origin for cancer therapy and chemoprevention. Current Drug Targets 7(3): 237-238

Do, Q-Tuan.; Bernard, P. 2004: Pharmacognosy and reverse pharmacognosy: a new concept for accelerating natural drug discovery. Idrugs: the Investigational Drugs Journal 7(11): 1017-1027

Hladik, J. 1954: Pharmacognosy at the Charles University. Ceskoslovenska Farmacie 3(5): 155-160

Braun, H. 1954: Pharmacognosy for the physician. Medizinische Monatsschrift 8(2): 80-81

Baytop, T. 1958: Pharmacognosy of Ephedra major Host var. procera. Tip Fakultesi Mecmuasi 21(3): 518-526

Loos, W. 1953: Pharmacognosy of Gelsemium sempervirens Ait. Arzneimittel-Forschung 3(8): 437-438

Mehra, P.N.; Mittal, T.C. 1961: Pharmacognosy of Indian substitutes of male fern. I. Dryopteris ramosa (Hope) C. Chr. and D. chrysocoma (Christ) C. Chr. Journal of Pharmacy and Pharmacology 13: 300-308

Kaiser, H.; Geyer, H. 1955: Pharmacognosy of copalche bark. Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft 288(6): 253-271

Go, L.S.; Hegnauer, R. 1955: Pharmacognosy of seven varieties of Datura stramonium. Pharmaceutisch Weekblad 90(15): 513-519

Tanaka, T. 2005: Pharmacoinformatics and pharmacogenomics. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 126(2): 113-116

Kereiakes, D.J.; Tcheng, J.; Fry, E.T.A.; Bhatt, D.L.; Bosker, G.; Diez, J.G.; Ferguson, J.J.; Levine, G.N.; Schaer, G.L.; Zidar, J. 2003: Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS. Journal of Invasive Cardiology 15(9): 536-553

Mula, M.; Trimble, M.R. 2003: Pharmacokinetic Interactions between Antiepileptic and Antidepressant Drugs. World Journal of Biological Psychiatry: the Official Journal of the World Federation of Societies of Biological Psychiatry 4(1): 21-24

Gladtke, E.; Fleischer, K. 1964: Pharmacokinetic Studies on Intraconchal Drug Administration. Monatsschrift für Kinderheilkunde 112: 104-106

Rind, H.; Gladtke, E. 1964: Pharmacokinetic Studies on Sulfonamide Therapy in 3-Month-Old Children. Monatsschrift für Kinderheilkunde 112: 239-240

Gladtke, E. 1964: Pharmacokinetic Testing of the Totality of Absorption by the Dost Method. Antibiotica et Chemotherapia. Fortschritte. Advances. Progres 12: 159-169

Lee, J.B.; Winstead, P.S.; Cook, A.M. 2006: Pharmacokinetic alterations in obesity. Orthopedics 29(11): 984-988

Inoue, A.; Saijo, Y.; Kikuchi, T.; Gomi, K.; Suzuki, T.; Maemondo, M.; Miki, M.; Sato, T.; Nukiwa, T. 2004: Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Annals of Oncology: Official Journal of the European Society for Medical Oncology 15(1): 51-54

Oshida, K.; Nagashima, T.; Ueda, T.; Yagata, H.; Tanabe, N.; Nakano, S.; Nikaidou, T.; Funatsu, H.; Hashimoto, H.; Miyazaki, M. 2005: Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography. European Radiology 15(7): 1353-1360

Yokoyama, Y.; Futagami, M.; Higuchi, T.; Mizunuma, H. 2006: Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report. European Journal of Gynaecological Oncology 27(4): 437-439

Black, R.E.; Gertler, R.; Wright, P.M.C.; Cancemi, M.T.; Hein, H.A.Tillmann.; Ramsay, M.A.E. 2003: Pharmacokinetic analysis of rapacuronium and its metabolite during liver transplantation: an assessment of its potential as a pharmacodynamic probe. Proceedings 16(3): 275-279

Kandimalla, K.K.; Curran, G.L.; Holasek, S.S.; Gilles, E.J.; Wengenack, T.M.; Poduslo, J.F. 2005: Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. Journal of Pharmacology and Experimental Therapeutics 313(3): 1370-1378

Mudhakir, D.; Akita, H.; Khalil, I.A.; Futaki, S.; Harashima, H. 2005: Pharmacokinetic analysis of the tissue distribution of octaarginine modified liposomes in mice. Drug Metabolism and Pharmacokinetics 20(4): 275-281

Chono, S.; Tauchi, Y.; Morimoto, K. 2006: Pharmacokinetic analysis of the uptake of liposomes by macrophages and foam cells in vitro and their distribution to atherosclerotic lesions in mice. Drug Metabolism and Pharmacokinetics 21(1): 37-44

Caliceti, P.; Veronese, F.M. 2003: Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Advanced Drug Delivery Reviews 55(10): 1261-1277

Jhee, O.H.; Lee, Y.S.; Shaw, L.M.; Jeon, Y.C.; Lee, M.H.; Lee, S.H.; Kang, J.S. 2007: Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC-MS/MS method. Clinica Chimica Acta; International Journal of Clinical Chemistry 375(1-2): 69-75

Lohitnavy, M.; Lohitnavy, O.; Chaijittiprasert, K.; Taytiwat, P.; Polnok, S.; Sareekan, K. 2003: Pharmacokinetic and bloequivalence studies of generic clarithromycin tablets in healthy male volunteers. Die Pharmazie 58(1): 72-73

Musch, E.; Loos, U.; Alléra, A.; Hügl, E.; Pütz, I.; Malek, M. 1989: Pharmacokinetic and cell-biological investigation of prednimustine compared to its components chlorambucil and prednisolone. Journal of ChemoTherapy 1(4 Suppl): 1127-1129

Neu, H.C. 1989: Pharmacokinetic and clinical studies of cefixime: a worldwide review. Journal of ChemoTherapy 1(4 Suppl): 531-533

Federspil, P.; Koch, A.; Schedler, M.; Tiesler, E. 1989: Pharmacokinetic and clinical studies on timentin in ear, nose and throat infections. Journal of ChemoTherapy 1(4 Suppl): 500-501

Begué, P.; Béfékadu, E.; Laplane, R. 1977: Pharmacokinetic and clinical study of cefazoline in children. Annales de Pediatrie 24(8-9): 617-620

Gusella, M.; Crepaldi, G.; Barile, C.; Bononi, A.; Menon, D.; Toso, S.; Scapoli, D.; Stievano, L.; Ferrazzi, E.; Grigoletto, F.; Ferrari, M.; Padrini, R. 2006: Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology 17(11): 1656-1660

Miyamoto, Y.; Uno, T.; Yamamoto, H.; Xiao-Kang, L.; Sakamoto, K.-I.; Hashimoto, H.; Takenaka, H.; Kawashima, Y.; Kawarasaki, H. 2004: Pharmacokinetic and immunosuppressive effects of tacrolimus-loaded biodegradable microspheres. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 10(3): 392-396

Parac-Vogt, T.N.; Vander Elst, L.; Kimpe, K.; Laurent, S.; Burtéa, C.; Chen, F.; Van Deun, R.; Ni, Y.; Muller, R.N.; Binnemans, K. 2006: Pharmacokinetic and in vivo evaluation of a self-assembled gadolinium(III)-iron(II) contrast agent with high relaxivity. Contrast Media and Molecular Imaging 1(6): 267-278

Shitara, Y.; Sugiyama, Y. 2006: Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology and Therapeutics 112(1): 71-105

Ohno, Y.; Iga, T.; Yamada, Y.; Nagahara, M.; Araie, M.; Takayanagi, R. 2005: Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG). Current Eye Research 30(4): 319-328

Pea, F.; Pavan, F.; Lugatti, E.; Dolcet, F.; Talmassons, G.; Screm, M.C.; Furlanut, M. 2006: Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. Clinical Pharmacokinetics 45(3): 287-295

Metra, M.; Dei Cas, L.; Cleland, J.G.F. 2006: Pharmacokinetic and pharmacodynamic characteristics of beta-blockers: when differences may matter. Journal of Cardiac Failure 12(3): 177-181

Gan, T.J. 2006: Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. Clinical Pharmacokinetics 45(9): 855-869

Ebi, H.; Sigeoka, Y.; Saeki, T.; Kawada, K.; Igarashi, T.; Usubuchi, N.; Ueda, R.; Sasaki, Y.; Minami, H. 2005: Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). Cancer ChemoTherapy and Pharmacology 56(2): 205-211

Mahmood, I.; Green, M.D. 2005: Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clinical Pharmacokinetics 44(4): 331-347

Jin, F.; Tayab, Z.R.; Balthasar, J.P. 2006: Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia. Aaps Journal 7(4): E895-E902

Svetyĭ, L.I.; Alekhin, S.N. 2002: Pharmacokinetic and pharmacodynamic effects of isradipine in patients with arterial hypertension. Eksperimental'naia i Klinicheskaia Farmakologiia 65(5): 35-38

Schall, U.; Pries, E.; Katta, T.; Klöppel, A.; Gastpar, M. 1996: Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone. Addiction Biology 1(1): 105-113

McKinnon, P.S.; Davis, S.L. 2004: Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. European Journal of Clinical Microbiology and Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 23(4): 271-288

Nuermberger, E.; Grosset, J. 2004: Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. European Journal of Clinical Microbiology and Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 23(4): 243-255

Moise, P.A.; Schentag, J.J. 1998: Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy. Current Opinion in Infectious Diseases 11(6): 673-680

Molinengo, L. 1960: Pharmacokinetic and pharmacodynamic observations on surface local anesthetics. II. Dose-effect ratios and time-effect ratios as means for the measurement of pharmacodynamic constants. Archivio Italiano di Scienze Farmacologiche 10: 308-324

Molinengo, L. 1960: Pharmacokinetic and pharmacodynamic observations on surface local anesthetics. Note 1. Mechanism of fixation and detoxication. Archivio Italiano di Scienze Farmacologiche 10: 141-165

Derom, E.; Pauwels, R.A. 2005: Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. Clinical Pharmacokinetics 44(8): 815-836

Haas, C.E.; Forrest, A. 2006: Pharmacokinetic and pharmacodynamic research in the intensive care unit: an unmet need. Critical Care Medicine 34(6): 1831-1833

Lewis, A.L.; Taylor, R.R.; Hall, B.; Gonzalez, M.V.; Willis, S.L.; Stratford, P.W. 2006: Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. Journal of Vascular and Interventional Radiology: Jvir 17(8): 1335-1343

Kurowski, M.; Sternfeld, T.; Sawyer, A.; Hill, A.; Möcklinghoff, C. 2003: Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Medicine 4(2): 94-100

Boucher, B.A.; Wood, G.C.; Swanson, J.M. 2006: Pharmacokinetic changes in critical illness. Critical Care Clinics 22(2): 255-271 Vi

Lee, E.J.; Kim, E.J.; Kim, Y.G.; Chung, H.C.; Kim, S.H.; Kim, D.H.; Lee, I.; Kim, S.G.; Lee, M.G. 2002: Pharmacokinetic changes of intravenous 2-(allylthio) pyrazine, a chemoprotective agent, in rats with acute renal failure induced by uranyl nitrate. Research Communications in Molecular Pathology and Pharmacology 111(5-6): 225-236

Surma, M.J.; Wiewiórka, J.; Szadkowska, A.; Liniecki, J. 1999: Pharmacokinetic characteristics of 99mTc-Ethylene-l-dicysteine (99mTc-EC). Nuclear Medicine Review. Central and Eastern Europe 2(1): 20-27

Ren, P.; Huang, X.; Li, S.-Q.; Xu, S.-Y.; Wan, M.-H.; Zhou, Y.-X.; Zhou, Y.-W.; Tang, W.-F. 2006: Pharmacokinetic characteristics of ferulic acid in patients with different syndromes of deficiency of spleen qi, stagnation of liver qi and spleen deficiency, and excess of stomach heat. Zhong Xi Yi Jie he Xue Bao 4(2): 147-151

MacGregor, T.R.; Sabo, J.P.; Norris, S.H.; Johnson, P.; Galitz, L.; McCallister, S. 2004: Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clinical Trials 5(6): 371-382

Chaná, P.; Fierro, A.él.; Reyes-Parada, M.; Sáez-Briones, P. 2003: Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study. Revista Medica de Chile 131(6): 623-631

Tatami, S.; Yamamura, N.; Sarashina, A.; Yong, C.-L.; Igarashi, T.; Tanigawara, Y. 2004: Pharmacokinetic comparison of an angiotensin Ii receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method. Drug Metabolism and Pharmacokinetics 19(1): 15-23

Minami, H.; Ebi, H. 2005: Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR). Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(13): 2053-2057

Telatyńska-Smieszek, B.ła. 2002: Pharmacokinetic comparison of propranolol and atenolol in people with primary hypertension. Annales Academiae Medicae Stetinensis 48: 367-380

Hamidi, M.; Azadi, A.; Rafiei, P. 2006: Pharmacokinetic consequences of pegylation. Drug Delivery 13(6): 399-409

Boffito, M.; Moyle, G.J. 2004: Pharmacokinetic considerations for combining 2 protease inhibitors. Aids Reader 14(3): 110-112; 115-116

Motl, S.; Zhuang, Y.; Waters, C.M.; Stewart, C.F. 2006: Pharmacokinetic considerations in the treatment of CNS tumours. Clinical Pharmacokinetics 45(9): 871-903

Wolraich, M.L.; Doffing, M.A. 2004: Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. Cns Drugs 18(4): 243-250

Gilman, J.T.; Duchowny, M.; Campo, A.E. 2003: Pharmacokinetic considerations in the treatment of childhood epilepsy. Paediatric Drugs 5(4): 267-277

Toma, M.B.; Smith, K.M.; Martin, C.A.; Rapp, R.P. 2006: Pharmacokinetic considerations in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. Orthopedics 29(6): 497-501

Launay-Vacher, V.; Izzedine, H.; Deray, G. 2005: Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clinical Pharmacokinetics 44(3): 221-235

Staatz, C.E.; Tett, S.E. 2005: Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. Drugs and Aging 22(7): 541-557

Perlík, F.; Masri, M.A.; Rost, M.; Kamarád, V.ĕc. 2005: Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients. Biomedical Papers of the Medical Faculty of the University Palacky Olomouc Czechoslovakia 149(2): 309-313

Furneri, P.M.; Roccasalva, L.; Fallica, L.; Tempera, G. 1989: Pharmacokinetic data and therapeutic efficacy of miocamycin: serum, urinary and prostatic levels. Therapeutic aspects in acute urethral syndrome and non-gonococcal urethritis. Journal of ChemoTherapy 1(4 Suppl): 581-582

Shi, J.-M.; Lai, S.-G.; Xu, C.-J.; Duan, G.-L.; Li, D. 2004: Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats. Acta Pharmacologica Sinica 25(8): 996-999

Hey, H.; Schmedes, A.; Lund, E.D.; Haslund-Vinding, P. 2004: Pharmacokinetic differences in the ingestion of alcopops versus pure ethanol. Ugeskrift for Laeger 166(49): 4471-4474

Schechter, T.; Finkelstein, Y.; Doyle, J.; Verjee, Z.; Moretti, M.; Koren, G.; Dupuis, L.L. 2007: Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 13(3): 307-314

Turnheim, K. 2005: Pharmacokinetic dosage guidelines for elderly subjects. Expert Opinion on Drug Metabolism and Toxicology 1(1): 33-48

Karie, S.; Launay-Vacher, V.; Kozlovskaia, N.L.; Izzedine, H.; Deray, G.; Shilov, E.M. 2005: Pharmacokinetic drug changes in patients with renal failure. Terapevticheskii Arkhiv 77(6): 78-82

Ludbrook, G.L.; Upton, R.N. 2003: Pharmacokinetic drug interaction between propofol and remifentanil?. Anesthesia and Analgesia 97(3): 924-925

Blume, H.; Donath, F.; Warnke, A.é; Schug, B.S. 2006: Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety 29(9): 769-784

Zhang, H.; Cui, D.; Wang, B.; Han, Y.-H.; Balimane, P.; Yang, Z.; Sinz, M.; Rodrigues, A.D. 2007: Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clinical Pharmacokinetics 46(2): 133-157

Swaisland, H.C.; Ranson, M.; Smith, R.P.; Leadbetter, J.; Laight, A.; McKillop, D.; Wild, M.J. 2005: Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clinical Pharmacokinetics 44(10): 1067-1081

Armstrong, S.C.; Cozza, K.L. 2003: Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part Ii. Psychosomatics 44(6): 515-520

Armstrong, S.C.; Cozza, K.L. 2003: Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part i. Psychosomatics 44(2): 167-171

Ma, Q.; Okusanya, O.O.; Smith, P.F.; Dicenzo, R.; Slish, J.C.; Catanzaro, L.M.; Forrest, A.; Morse, G.D. 2005: Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opinion on Drug Metabolism and Toxicology 1(3): 473-485

Halcomb, S.E.; Sivilotti, M.L.A.; Goklaney, A.; Mullins, M.E. 2005: Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine 12(2): 169-172

Napolov, I.K.; Korobkova, I.Z.; Cherkavskaia, O.V.; Kalinichev, S.A. 2006: Pharmacokinetic essentials of adverse reactions of radiopaque contrast agents. Vestnik Rentgenologii i Radiologii 2: 52-61

Kong, L.; Cooperwood, J.S.; Huang, S.-H.C.; Chu, C.K.; Boudinot, F.D. 2003: Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine. Antiviral Chemistry and ChemoTherapy 14(5): 263-270

Hammond, L.A. 2003: Pharmacokinetic evaluation of gefitinib when administered with chemotherapy. Clinical Lung Cancer 5(Suppl 1): S18-S21

Cattel, L.; Airoldi, M.; Delprino, L.; Passera, R.; Milla, P.; Pedani, F. 2006: Pharmacokinetic evaluation of gemcitabine and 2',2'-difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors. Annals of Oncology: Official Journal of the European Society for Medical Oncology 17(Suppl 5): V142-V147

Krishnaiah, Y.S.R.; Muzib, Y.Indira.; Bhaskar, P.; Satyanarayana, V.; Latha, K. 2003: Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of tinidazole in healthy human volunteers. Drug Delivery 10(4): 263-268

Krishnaiah, Y.S.R.; Veer Raju, P.; Dinesh Kumar, B.; Jayaram, B.; Rama, B.; Raju, V.; Bhaskar, P. 2003: Pharmacokinetic evaluation of guar gum-based colon-targeted oral drug delivery systems of metronidazole in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics 28(4): 287-294

Novelli, A.; Adembri, C.; Livi, P.; Fallani, S.; Mazzei, T.; De Gaudio, A.R. 2005: Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clinical Pharmacokinetics 44(5): 539-549

Leather, H.; Boyette, R.M.; Tian, L.; Wingard, J.R. 2006: Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin a in allogeneic hematopoietic stem cell transplant recipients. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 12(3): 325-334

Kolyvanov, G.B. 2004: Pharmacokinetic evaluation of the tablet dosage forms of gidazepam prepared by various technologies. Eksperimental'naia i Klinicheskaia Farmakologiia 67(2): 63-66

Tseng, A.H.; Harding, J.W.; Craft, R.M. 2004: Pharmacokinetic factors in sex differences in Delta 9-tetrahydrocannabinol-induced behavioral effects in rats. Behavioural Brain Research 154(1): 77-83

Wyllie, M. 2003: Pharmacokinetic fixes for pharmacodynamic deficits. Bju International 92(4): 483-484

Beier, M.T. 2005: Pharmacokinetic interaction and erythromycin-induced sudden cardiac death: implications for practice. Journal of the American Medical Directors Association 6(2): 154

Reyderman, L.; Kosoglou, T.; Boutros, T.; Seiberling, M.; Statkevich, P. 2004: Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Current Medical Research and Opinion 20(9): 1493-1500

Federico, S.; Carrano, R.; Capone, D.; Gentile, A.; Palmiero, G.; Basile, V. 2006: Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation. Clinical Pharmacokinetics 45(2): 169-175

Zarychanski, R.; Wlodarczyk, K.; Ariano, R.; Bow, E. 2006: Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate. Journal of Antimicrobial ChemoTherapy 58(1): 228-230

Llinares-Tello, F.; Hernández-Prats, C.; Pastor-Climente, I.; Escrivá-Moscardó, S. 2007: Pharmacokinetic interaction between phenitoin and dexibuprofen resulting in acute neurologic toxicity. Medicina Clinica 128(6): 239

Mallolas, J.; Sarasa, M.; Nomdedeu, M.; Soriano, A.; López-Púa, Y.; Blanco, J.L.; Martínez, E.; Gatell, J.M. 2007: Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Medicine 8(2): 131-134

Kunicki, P.ł K.; Sobieszczańska-Małek, M.łg. 2005: Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient. Therapeutic Drug Monitoring 27(1): 107-108

Llinares Tello, F.; Bosacoma Ros, N.; Hernández Prats, C.; Climent Grana, E.; Selva Otaolaurruchi, J.; Ordovás Baines, J.P. 2003: Pharmacokinetic interaction between valproic acid and carbapenem-like antibiotics: a discussion of three cases. Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 27(4): 258-263

Cabanes Mariscal, M.A.; Sánchez López, P.; Alvarez Herranz, P.; Chamorro Merino, G. 2006: Pharmacokinetic interaction between valproic acid and ertapenem. Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 30(5): 313-315

Perea Falomir, M.; Roura Poch, P.; Higueruelo Demasón, S.; García Gil, V.J. 2006: Pharmacokinetic interaction between valproic acid and imipenem. Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 30(5): 316-317

Clause, D.; Decleire, P.-Y.; Vanbinst, R.; Soyer, A.él.; Hantson, P. 2005: Pharmacokinetic interaction between valproic acid and meropenem. Intensive Care Medicine 31(9): 1293-1294

Khurana, M.; Lal, J.; Kamboj, V.P.; Nityanand, S.; Gupta, R.C. 2003: Pharmacokinetic interaction of tetracycline with centchroman in healthy female volunteers. Drugs in R&d 4(5): 293-299

Rasmussen, B.B.; Larsen, L.S.; Senderovitz, T. 2005: Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers. Bjog: An International Journal of Obstetrics and Gynaecology 112(11): 1492-1499

Leucuţa, A.; Vlase, L.; Farcău, D.; Nanulescu, M. 2004: Pharmacokinetic interaction study between ranitidine and metoclopramide. Romanian Journal of Gastroenterology 13(3): 211-214

Maas, B.; Kerr, T.; Fairbairn, N.; Montaner, J.; Wood, E. 2006: Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence. Expert Opinion on Drug Metabolism and Toxicology 2(4): 533-543

Obua, C.; Ntale, M.; Lundblad, M.S.; Mahindi, M.; Gustafsson, L.L.; Ogwal-Okeng, J.W.; Anokbonggo, W.W.; Hellgren, U. 2006: Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda. African Health Sciences 6(2): 86-92

Frassetto, L.; Thai, T.; Aggarwal, A.M.; Bucher, P.; Jacobsen, W.; Christians, U.; Benet, L.Z.; Floren, L.C. 2003: Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metabolism and Pharmacokinetics 18(2): 114-120

Calabresi, L.; Pazzucconi, F.; Ferrara, S.; Di Paolo, A.; Tacca, M.Del.; Sirtori, C. 2004: Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. Pharmacological Research 49(5): 493-499

Wanke, C. 2003: Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047, by Fichtenbaum et al. Aids 17 Suppl. 4: S109-S110

Steinborn, B. 2005: Pharmacokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in children and adolescents. Roczniki Akademii Medycznej W Bialymstoku 50(Suppl 1): 9-15

Bialer, M.; Doose, D.R.; Murthy, B.; Curtin, C.; Wang, S.-S.; Twyman, R.E.; Schwabe, S. 2004: Pharmacokinetic interactions of topiramate. Clinical Pharmacokinetics 43(12): 763-780

Scheen, A.é J. 2007: Pharmacokinetic interactions with thiazolidinediones. Clinical Pharmacokinetics 46(1): 1-12

Wiegand, H.ör.; Wirz, B.; Schweitzer, A.; Gross, G.; Perez, M.I.R.; Andres, H.; Kimmerlin, T.; Rueping, M.; Seebach, D. 2004: Pharmacokinetic investigation of a 14C-labelled beta 3/alpha tetrapeptide in rats. Chemistry and Biodiversity 1(11): 1812-1828

Sathyan, G.; Xu, E.; Thipphawong, J.; Gupta, S.K. 2007: Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. Bmc Clinical Pharmacology 7: 3

Li, Q.; Lugt, C.B.; Looareesuwan, S.; Krudsood, S.; Wilairatana, P.; Vannaphan, S.; Chalearmrult, K.; Milhous, W.K. 2004: Pharmacokinetic investigation on the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene 71(6): 723-731

Barbacioru, C.; Arunachalam, A.; Cowden, D.; Kahwash, E.; Saltz, J.H. 2003: Pharmacokinetic mapping of breast tumors: a new statistical analysis technique for dynamic magnetic resonance imaging. AMIA . Annual Symposium Proceedings. AMIA Symposium 2003: 783

Yang, X-Xia.; Hu, Z-Ping.; Chan, S.Yung.; Duan, W.; Ho, P.Chi-Liu.; Boelsterli, U.Alex.; Ng, K-Yun.; Chan, E.; Bian, J-Song.; Chen, Y-Zong.; Huang, M.; Zhou, S-Feng. 2006: Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide. Current Drug Metabolism 7(4): 431-455

Wikinski, S. 2005: Pharmacokinetic mechanisms underlying resistance in psychopharmacological treatment. the role of P-glycoprotein. Vertex 16(64): 438-441

Murthy, B.P.; Skee, D.M.; Danyluk, A.P.; Brett, V.; Vorsanger, G.J.; Moskovitz, B.L. 2007: Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol. Current Medical Research and Opinion 23(2): 275-284

Jin, F.; Krzyzanski, W. 2004: Pharmacokinetic model of target-mediated disposition of thrombopoietin. Aaps Pharmsci 6(1): E9

Gallo, J.M.; Vicini, P.; Orlansky, A.; Li, S.; Zhou, F.; Ma, J.; Pulfer, S.; Bookman, M.A.; Guo, P. 2004: Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 10(23): 8048-8058

Andersen, M.E.; Clewell, H.J.; Tan, Y.-M.; Butenhoff, J.L.; Olsen, G.W. 2006: Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives. Toxicology 227(1-2): 156-164

Tsuchiya, H.; Kuwata, K.; Nagayama, S.; Yamashita, K.; Kamiya, H.; Harashima, H. 2004: Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor. Drug Metabolism and Pharmacokinetics 19(3): 206-215

Urien, S.; Rezaí, K.; Lokiec, F.ço. 2005: Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. Journal of Pharmacokinetics and Pharmacodynamics 32(5-6): 817-833

Urien, S.; Laurent, N.; Barre, J.; Druguet, M.; Bouvier D'yvoire, M.; Maire, P. 2004: Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime--a population study in 25 elderly patients. European Journal of Clinical Pharmacology 60(1): 11-16

Muneoka, K.; Shirai, Y.; Yokoyama, N.; Wakai, T.; Hatakeyama, K. 2005: Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(2): 231-233

Muneoka, K.; Shirai, Y.; Wakai, T.; Yokoyama, N.; Okumura, S.; Hatakeyama, K. 2005: Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(6): 799-802

Fernández Megía, M.J.; Alós Almiñana, M.; Esquer Borrás, J. 2004: Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma. Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 28(6): 433-439

Fox, A.W.; Kori, S.H. 2005: Pharmacokinetic opportunities for combination therapy in migraine. Neurology 64(10 Suppl 2: S21-S25

Nyholm, D. 2006: Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. Clinical Pharmacokinetics 45(2): 109-136

Jia, G.; Heverhagen, J.T.; Henry, H.; Polzer, H.; Baudendistel, K.T.; von Tengg-Kobligk, H.; Levine, A.L.; Rosol, T.J.; Knopp, M.V. 2006: Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRi. Magnetic Resonance Imaging 24(6): 721-725

Leth, F.V.; Kappelhoff, B.S.; Johnson, D.; Losso, M.H.; Boron-Kaczmarska, A.; Saag, M.S.; Livrozet, J.-M.; Hall, D.B.; Leith, J.; Huitema, A.D.R.; Wit, F.W.; Beijnen, J.H.; Lange, J.M.A. 2006: Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. Aids Research and Human Retroviruses 22(3): 232-239

Panomvana Na Ayudhya, D.; Suwanmanee, J.; Visudtibhan, A. 2006: Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. American Journal of Therapeutics 13(3): 211-217

Beccari, E.; Segre, G. 1961: Pharmacokinetic periodism. Archivio Italiano di Scienze Farmacologiche 11: 321-323

Morabito, S.; Guzzo, I.; Vitaliano, E.; Muzi, L.; Solazzo, A.; Pistolesi, V.; Pierucci, A. 2006: Pharmacokinetic principles and drug-dosing adjustments during continuous renal replacement therapies (CRRT). Giornale Italiano di Nefrologia: Organo Ufficiale Della Societa Italiana di Nefrologia 23(Suppl 36): S127-S138

Ereshefsky, L.; Mannaert, E. 2005: Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs in R&d 6(3): 129-137

Siafaka, I.; Rellia, P.; Argyra, E.; Iakovidou, N.; Sykiotis, C.; Vadalouka, A. 2004: Pharmacokinetic profile and efficacy of a fentanyl transdermal delivery system for acute postoperative pain after intra-abdominal gynecologic surgery for cancer. Pain Practice: the Official Journal of World Institute of Pain 4(2): 98-104

Sathyan, G.; Xu, E.; Thipphawong, J.; Gupta, S.K. 2007: Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food. Bmc Clinical Pharmacology 7: 2

Walls, C.; Lewis, A.; Bullman, J.; Boswell, D.; Summers, S.J.; Dow, A.; Sidhu, J. 2004: Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Current Medical Research and Opinion 20(6): 803-809

Reoux, J.P.; Saxon, A.J.; Shen, D. 2006: Pharmacokinetic profile of an oral loading dose of divalproex sodium during acute alcohol withdrawal. Journal of Clinical Psychopharmacology 26(1): 105-107

Delbaldo, C.; Pierga, J-Yves.; Dieras, Véronique.; Faivre, S.; Laurence, Vérie.; Vedovato, J-Claude.; Bonnay, M.; Mueser, M.; Nolting, A.; Kovar, A.; Raymond, E. 2005: Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. European Journal of Cancer 41(12): 1739-1745

Persiani, S.; D'Amato, M.; Jakate, A.; Roy, P.; Wangsa, J.; Kapil, R.; Rovati, L.C. 2006: Pharmacokinetic profile of dexloxiglumide. Clinical Pharmacokinetics 45(12): 1177-1188

Wiltshire, H.; Hirankarn, S.; Farrell, C.; Paya, C.; Pescovitz, M.D.; Humar, A.; Dominguez, E.; Washburn, K.; Blumberg, E.; Alexander, B.; Freeman, R.; Heaton, N. 2005: Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clinical Pharmacokinetics 44(5): 495-507

Bronstein, M.; Musolino, N.; Jallad, R.; Cendros, J.M.; Ramis, J.; Obach, R.; Leselbaum, A.; Catus, F. 2005: Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clinical Endocrinology 63(5): 514-519

Mannaert, E.; Vermeulen, A.; Remmerie, B.; Bouhours, P.; Levron, J.C. 2005: Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. L'Encephale 31(5 Part 1): 609-615

Massie, J.; Cranswick, N. 2006: Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. Journal of Paediatrics and Child Health 42(10): 601-605

Okada, Y.; Kawamoto, M.; Fujii, K.; Yuge, O. 2000: Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults. Journal of Anesthesia 14(3): 124-127

Shimizu, T.; Miyashita, I.; Matsubara, Y.; Ikeda, M.; Yamaguchi, M. 2006: Pharmacokinetic profile of silodosin in clinical practice. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 126 Spec No.: 257-263

Penetar, D.M.; Teter, C.J.; Ma, Z.; Tracy, M.; Lee, D.Y.-W.; Lukas, S.E. 2006: Pharmacokinetic profile of the isoflavone puerarin after acute and repeated administration of a novel kudzu extract to human volunteers. Journal of Alternative and Complementary Medicine 12(6): 543-548

Tomlinson, B.; Thomas, N.G.; Lan, I.W.; Barbanoj, M.; Antonijoan, R.M.; Drazna, E.; Ramis, J.; Obach, R.; Peraire, C.ón. 2006: Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency. Clinical Pharmacokinetics 45(10): 1003-1011

Chen, J.-W.; Lauritzen, T.; Christiansen, J.J.; Jensen, L.H.; Clausen, W.H.O.; Christiansen, J.S. 2005: Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with Type 1 diabetes: a randomized double-blinded crossover study. Diabetic Medicine: a Journal of the British Diabetic Association 22(3): 273-277

Seydel, J.K. 1972: Pharmacokinetic properties and their relation to certain physicochemical properties. European Journal of Toxicology and Hygiene of Environment 5(5 Suppl): 39-52

Darwish, M.; Kirby, M.; Robertson, P.; Tracewell, W.; Jiang, J.G. 2006: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clinical Therapeutics 28(5): 707-714

Burger, H.; Nooter, K. 2004: Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 3(12): 1502-1505

Hing, J.P.; Piotrovsky, V.; Kimko, H.; Brashear, H.R.; Zhao, Q. 2005: Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Current Medical Research and Opinion 21(4): 483-488

Iakovleva, I.I.; Timokhov, V.S. 2004: Pharmacokinetic simulation of different modes of renal replacement therapy. Anesteziologiia i Reanimatologiia 6: 16-23

Kunisawa, T.; Nagata, O.; Iwasaki, H. 2006: Pharmacokinetic simulation of high-dose administration of dexmedetomidine for decubitus treatment. Masui. Japanese Journal of Anesthesiology 55(8): 995-998

Proost, J.H. 2006: Pharmacokinetic simulations and AUC: center specificity in the limited sampling model. International Journal of Clinical Pharmacology and Therapeutics 44(6): 292-3; author reply 293-5

Groninger, E.; Proost, J.H.; de Graaf, S.S.N. 2004: Pharmacokinetic studies in children with cancer. Critical Reviews in Oncology/Hematology 52(3): 173-197

Rolan, P. 2004: Pharmacokinetic studies in migraine: what questions should physicians ask?. Current Pain and Headache Reports 8(3): 219-222

Pang, H.; Wang, H.L.; Fu, L.; Su, C.Y. 2001: Pharmacokinetic studies of 20(R)-ginsenoside RG3 in human volunteers. Yao Xue Xue Bao 36(3): 170-173

Nnane, I.P.; Kadaba, P.K. 2004: Pharmacokinetic studies of a novel anticonvulsant, 2-(4-chlorophenyl)amino-2-(4-pyridyl)ethane, in rats. Pharmacological Research 49(2): 177-183

Shao, W.; Xu, W.; Li, A.; Xi, Y.; Wang, C. 2005: Pharmacokinetic studies of quercetin-hydroxypropyl-beta-cyclodextrin inclusion compound in rats. Zhong Yao Cai 28(1): 47-50

Goudemand, J.; Scharrer, I.; Berntorp, E.; Lee, C.A.; Borel-Derlon, A.; Stieltjes, N.; Caron, C.; Scherrmann, J.M.; Bridey, F.; Tellier, Z.; Federici, A.B.; Mannucci, P.M. 2005: Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIIi content treated with three virus-inactivation/removal methods. Journal of Thrombosis and Haemostasis: Jth 3(10): 2219-2227

Bergström, M.; Långström, B. 2005: Pharmacokinetic studies with PET. Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progres des Recherches Pharmaceutiques 62: 279-317

Sharma, S.; Thawani, V.; Hingorani, L.; Shrivastava, M.; Bhate, V.R.; Khiyani, R. 2004: Pharmacokinetic study of 11-Keto beta-Boswellic acid. Phytomedicine: International Journal of PhytoTherapy and Phytopharmacology 11(2-3): 255-260

Yokoyama, K.; Miyatake, S.-I.; Kajimoto, Y.; Kawabata, S.; Doi, A.; Yoshida, T.; Asano, T.; Kirihata, M.; Ono, K.; Kuroiwa, T. 2006: Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT. Journal of Neuro-Oncology 78(3): 227-232

Moreno, J.; Belmont, A.; Jaimes, O.; Santos, J.é A.; López, G.; Campos, M.ía.G.; Amancio, O.; Pérez, P.; Heinze, G. 2004: Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. Archives of Medical Research 35(2): 168-171

Braybrooke, J.P.; Levitt, N.C.; Joel, S.; Davis, T.; Madhusudan, S.; Turley, H.; Wilner, S.; Harris, A.L.; Talbot, D.C. 2003: Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 9(13): 4682-4688

Fujimiya, T.; Ohbora, Y.; Shinagawa, H.; Aki, T. 2003: Pharmacokinetic study of ethanol and its metabolites during ethanol infusion. Legal Medicine 5(Suppl 1): S126-S128

Fujimiya, T.; Shinagawa, H.; Ohbora, Y.; Aki, T. 2003: Pharmacokinetic study of ethanol and its metabolites in culture cells. Legal Medicine 5(Suppl 1): S123-S125

Ye, M.; Lin, X.-x.; Pan, H.-m.; Li, N.; Lou, F.; Jin, W.; Zheng, Y.; Wu, J.-m. 2005: Pharmacokinetic study of intraperitoneal chemotherapy with HCPT. Zhongguo Zhong Yao Za Zhi 30(20): 1610-1612

Bassi, P.; De Marco, V.; Tavolini, I.M.; Longo, F.; Pinto, F.; Zucchetti, M.; Crucitta, E.; Marini, L.; Dal Moro, F. 2005: Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy. Urologia Internationalis 75(4): 309-313

Abe, Y.; Tsuji, Y.; Hisano, M.; Nakada, M.; Miura, K.; Watanabe, S.; Odajima, Y.; Iikura, Y. 2004: Pharmacokinetic study of mizoribine in an adolescent with lupus nephritis. Pediatrics International: Official Journal of the Japan Pediatric Society 46(5): 597-600

Kobayashi, M.; Sakamoto, J.; Namikawa, T.; Okamoto, K.; Okabayashi, T.; Ichikawa, K.; Araki, K. 2006: Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World Journal of Gastroenterology 12(9): 1412-1415

Mangel, J.; Buckstein, R.; Imrie, K.; Spaner, D.; Franssen, E.; Pavlin, P.; Boudreau, A.; Pennell, N.; Combs, D.; Berinstein, N.L. 2003: Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Annals of Oncology: Official Journal of the European Society for Medical Oncology 14(5): 758-765

Niwa, T.; Nakamura, A.; Kato, T.; Kutsuna, T.; Katou, K.; Morita, H.; Kojima, Y.; Itoh, M. 2006: Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. Respiratory Medicine 100(2): 324-331

Li, X.-k.; Xu, H.; Zhao, W.; Zheng, Q.; Huang, Y.-d.; Wu, X.-p.; Liu, C.-z. 2002: Pharmacokinetic study of recombinant human acidic fibroblast growth factor in rabbits by skin external use. Yao Xue Xue Bao 37(6): 424-427

Saint-Marcoux, F.; Knoop, C.; Debord, J.; Thiry, P.; Rousseau, A.; Estenne, M.; Marquet, P. 2005: Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clinical Pharmacokinetics 44(12): 1317-1328

Lumlertgul, D.; Noppakun, K.; Rojanasthien, N.; Kanchanarattanakorn, K.; Jittikanont, S.; Manoyot, A.; Bunnachak, D.; Ophascharoensuk, V. 2006: Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients. Journal of the Medical Association of Thailand 89(Suppl 2): S73-S78

Kobayashi, M.; Oba, K.; Sakamoto, J.; Kondo, K.; Nagata, N.; Okabayashi, T.; Namikawa, T.; Hanazaki, K. 2007: Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 10(1): 52-57

Fu, L.; Dai, Z.; Hou, S.; Wan, Y. 2004: Pharmacokinetic study on lovastatin sustained-release tablet and sustained-release capsule in Beagal dogs. Journal of Huazhong University of Science and Technology. Medical Sciences 24(2): 116-119

Han, G.-z.; Ren, H.-c.; Lu, Y.; Li, Y.; Xiao, S.; Ye, H.-w.; Wang, H.-m. 2006: Pharmacokinetic study with N-Ile1-Thr2-63-desulfato-r-hirudin in rabbits by means of bioassay. Journal of Zhejiang University. Science. B 7(3): 241-244

Aleksandrova, S.g. 2004: Pharmacokinetic substantiation of ceftriaxone prophylaxis of hereditary syphilis. Antibiotiki i Khimioterapiia 49(6): 15-19

Longnecker, M.P. 2006: Pharmacokinetic variability and the miracle of modern analytical chemistry. Epidemiology 17(4): 350-351

Perucca, E. 2005: Pharmacokinetic variability of new antiepileptic drugs at different ages. Therapeutic Drug Monitoring 27(6): 714-717

Johannessen, S.I.; Tomson, T.ör. 2006: Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?. Clinical Pharmacokinetics 45(11): 1061-1075

Bandara, U.G.C.; Diyabalanage, S.; Hanke, C.; van Geldern, R.; Barth, J.A.C.; Chandrajith, R. 2018: Arsenic-rich shallow groundwater in sandy aquifer systems buffered by rising carbonate waters: a geochemical case study from Mannar Island, Sri Lanka. Science of the Total Environment 633: 1352-1359

Kuboyama, N.; Hayashi, I.; Yamaguchi, T. 2006: Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 127(3): 223-232

Li, Y.; Pan, W.S.; Chen, S.L.; Xu, H.X.; Yang, D.J.; Chan, A.S.C. 2006: Pharmacokinetic, tissue distribution, and excretion of puerarin and puerarin-phospholipid complex in rats. Drug Development and Industrial Pharmacy 32(4): 413-422

Matsui-Sakata, A.; Ohtani, H.; Sawada, Y. 2005: Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metabolism and Pharmacokinetics 20(3): 187-199

Piotrovsky, V. 2005: Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. Aaps Journal 7(3): E609-E624

Romberg, R.; Olofsen, E.; Sarton, E.; den Hartigh, J.; Taschner, P.E.M.; Dahan, A. 2004: Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 100(1): 120-133

Lötsch, J.ör. 2005: Pharmacokinetic-pharmacodynamic modeling of opioids. Journal of Pain and Symptom Management 29(5 Suppl): S90-103

Diack, C.; Bois, F.éd.ér.Y. 2005: Pharmacokinetic-pharmacodynamic models for categorical toxicity data. Regulatory Toxicology and Pharmacology: Rtp 41(1): 55-65

Woloszczuk-Gebicka, B.; Wyska, E.; Grabowski, T.; Swierczewska, A.; Sawicka, R. 2006: Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. Paediatric Anaesthesia 16(7): 761-768

Banerji, U.; Walton, M.; Raynaud, F.; Grimshaw, R.; Kelland, L.; Valenti, M.; Judson, I.; Workman, P. 2005: Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 11(19 Part 1): 7023-7032

Delbaldo, C.; Chatelut, E.; Ré, M.; Deroussent, A.; Séronie-Vivien, S.; Jambu, A.; Berthaud, P.; Le Cesne, A.; Blay, J.-Y.; Vassal, G. 2006: Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 12(20 Part 1): 6073-6078

Isla, A.; Canut, A.és.; Rodríguez-Gascón, A.; Labora, A.; Ardanza-Trevijano, B.; Solinís, M.ía.A.; Pedraz, J.é L. 2005: Pharmacokinetic/pharmacodynamic analysis of antibiotic therapy in dentistry and stomatology. Enfermedades Infecciosas y Microbiologia Clinica 23(3): 116-121

Del Mar Fernández de Gatta Garcia, M.; Revilla, N.; Calvo, M.V.; Domínguez-Gil, A.; Sánchez Navarro, A. 2007: Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Medicine 33(2): 279-285

Sánchez Navarro, A. 2005: Pharmacokinetic/pharmacodynamic analysis to optimize antibacterial treatments: prediction of efficacy by using Montecarlo simulation techniques. Revista Espanola de Quimioterapia: Publicacion Oficial de la Sociedad Espanola de Quimioterapia 18(3): 230-235

Tod, M.; Farcy-Afif, M.; Stocco, J.; Boyer, N.; Bouton, Vérie.; Sinègre, M.; Marcellin, P. 2005: Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Clinical Pharmacokinetics 44(4): 417-428

Schuck, E.L.; Derendorf, H. 2005: Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Review of AntI-Infective Therapy 3(3): 361-373

Isla, A.; Canut, A.és.; Gascón, A.R.; Labora, A.; Ardanza-Trevijano, B.; Solinís, M.A.és.; Pedraz, J.L. 2005: Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections. Clinical Pharmacokinetics 44(3): 305-316

Tayab, Z.R.; Hochhaus, G.ün. 2005: Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. Expert Opinion on Drug Delivery 2(3): 519-532

Boak, L.M.; Li, J.; Rayner, C.R.; Nation, R.L. 2007: Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrobial Agents and ChemoTherapy 51(4): 1287-1292

Toutain, P.-L. 2002: Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. Aaps Pharmsci 4(4): E38

Mazoit, J.-X. 2006: Pharmacokinetic/pharmacodynamic modeling of anesthetics in children: therapeutic implications. Paediatric Drugs 8(3): 139-150

Tornøe, C.W.; Agersø, H.; Nielsen, H.A.; Madsen, H.; Jonsson, E.Niclas. 2004: Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME. Journal of Pharmacokinetics and Pharmacodynamics 31(6): 441-461

Mouton, J.W.; Vinks, A.A. 2005: Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clinical Pharmacokinetics 44(2): 201-210

Mégarbane, B.; Bloch, V.; Deye, N.; Baud, Fédéric.J. 2007: Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose. Intensive care medicine 33(1): 195-6; author reply 197

Meagher, A.K.; Ambrose, P.G.; Grasela, T.H.; Ellis-Grosse, E.J. 2005: Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagnostic Microbiology and Infectious Disease 52(3): 165-171

Theuretzbacher, U.; Ihle, F.; Derendorf, H. 2006: Pharmacokinetic/pharmacodynamic profile of voriconazole. Clinical Pharmacokinetics 45(7): 649-663

Avramis, V.I.; Panosyan, E.H. 2005: Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clinical Pharmacokinetics 44(4): 367-393

Trocóniz, I.F. 2002: Pharmacokinetic/pharmacodynamic relationships: basic concepts. Methods and Findings in Experimental and Clinical Pharmacology 24 Suppl D: 125-126

Hilger, R.A.; Richly, H.; Grubert, M.; Oberhoff, C.; Strumberg, D.; Scheulen, M.E.; Seeber, S. 2005: Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil. International Journal of Clinical Pharmacology and Therapeutics 43(12): 588-589

Hitzenberger, G. 1964: Pharmacokinetics and Clinico-Therapeutic Effectiveness of 4-Sulfanilamido-5,6-Dimethoxypyrimidine. Wiener Klinische Wochenschrift 76: 330-334

Jenne, J.W. 1964: Pharmacokinetics and the Dose of Isoniazid and P-Aminosalicylic Acid in the Treatment of Tuberculosis. Antibiotica et Chemotherapia. Fortschritte. Advances. Progres 12: 407-432

Plancher, A.C.; Salvi, G.; Bacuzzi, E. 1964: Pharmacokinetics of 2-Sulfanilamido-5-Ethylpyrimidine in man. Il Farmaco; Edizione Pratica 19: 550-559

Droller, H. 1964: Pharmacokinetics of Inhalational Anaesthetics. Lancet 2(7351): 143-145

Hitzenberger, G.; Spitzy, K.H. 1964: Pharmacokinetics of Penicillin G in Conventional and Extremely High Dosage. Arzneimittel-Forschung 14: 19-23

Brown, D.B.; Cai, S.-R.; Fundakowski, C.E.; Zamboni, W.C.; Strychor, S.; McLeod, H.L. 2006: Pharmacokinetics after endovascular lung perfusion with Cisplatin. Journal of Vascular and Interventional Radiology: Jvir 17(5): 883-888

Van Putte, B.P.; Hendriks, J.M.H.; Romijn, S.; Pauwels, B.; De Boeck, G.; Guetens, G.; De Bruijn, E.; Van Schil, P.E.Y. 2003: Pharmacokinetics after pulmonary artery perfusion with gemcitabine. Annals of Thoracic Surgery 76(4): 1036-1040; Discussion 1040

Gefvert, O.; Eriksson, B.; Persson, P.; Helldin, L.; Björner, A.; Mannaert, E.; Remmerie, B.; Eerdekens, M.ël.; Nyberg, S. 2005: Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. International Journal of Neuropsychopharmacology 8(1): 27-36

Hirano, K.; Nakamura, K.; Hasegawa, M. 2005: Pharmacokinetics and adverse event of TS-1 administered through gastrostomy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(6): 859-862

Mackay, P.; Ynddal, L.; Andersen, J.V.; McCormack, J.G. 2003: Pharmacokinetics and anti-hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1,4-dideoxy-1,4-imino-d- arabinitol, in glucagon-challenged rats and dogs and in diabetic ob/ob mice. Diabetes Obesity and Metabolism 5(6): 397-407

Zhou, M.H.; Yu, Y.Q.; Duan, G.L.; Cheng, W.B.; Xu, C.J.; Liu, X. 2001: Pharmacokinetics and bioavailability of clinafloxacin in rats. Yao Xue Xue Bao 36(2): 134-136

Moon, Y.J.; Sagawa, K.; Frederick, K.; Zhang, S.; Morris, M.E. 2006: Pharmacokinetics and bioavailability of the isoflavone biochanin a in rats. Aaps Journal 8(3): E433-E442

Kowalski, P.; Bieniecki, M. 2006: Pharmacokinetics and bioavailability study of L-ornithine-L-aspartate in healthy volunteers--a comparative study of two oral formulations. Journal of Pharmaceutical and Biomedical Analysis 41(3): 1061-1064

Kaneo, Y.; Hashihama, S.; Kakinoki, A.; Tanaka, T.; Nakano, T.; Ikeda, Y. 2005: Pharmacokinetics and biodisposition of poly(vinyl alcohol) in rats and mice. Drug Metabolism and Pharmacokinetics 20(6): 435-442

Vallabhajosula, S.; Kuji, I.; Hamacher, K.A.; Konishi, S.; Kostakoglu, L.; Kothari, P.A.; Milowski, M.I.; Nanus, D.M.; Bander, N.H.; Goldsmith, S.J. 2005: Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111in or 177Lu?. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 46(4): 634-641

Chauhan, S.C.; Jain, M.; Moore, E.D.; Wittel, U.A.; Li, J.; Gwilt, P.R.; Colcher, D.; Batra, S.K. 2005: Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. European Journal of Nuclear Medicine and Molecular Imaging 32(3): 264-273

Jung, K.-H.; Kim, D.-H.; Paik, J.-Y.; Ko, B.-H.; Bae, J.-S.; Choe, Y.S.; Lee, K.-H.; Kim, B.-T. 2006: Pharmacokinetics and biodistribution of a small radioiodine labeled nerve growth factor fragment. Annals of Nuclear Medicine 20(8): 535-540

Healy, J.M.; Lewis, S.D.; Kurz, M.; Boomer, R.M.; Thompson, K.M.; Wilson, C.; McCauley, T.G. 2004: Pharmacokinetics and biodistribution of novel aptamer compositions. Pharmaceutical Research 21(12): 2234-2246

Amantana, A.; Iversen, P.L. 2005: Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Current Opinion in Pharmacology 5(5): 550-555

Reddy, L.Harivardhan.; Murthy, R.S.R. 2004: Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomedical Papers of the Medical Faculty of the University Palacky Olomouc Czechoslovakia 148(2): 161-166

Cho, H.Y.; Kang, H.A.; Lee, Y.B. 2006: Pharmacokinetics and bioequivalence evaluation of two gabapentin preparations after a single oral dose in healthy Korean volunteers. International Journal of Clinical Pharmacology and Therapeutics 44(8): 386-392

Najib, N.M.; Idkaidek, N.; Adel, A.; Admour, I.'; Astigarraga, R.E.B.; Nucci, G.D.; Alam, S.M.; Dham, R.; Qumaruzaman 2003: Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and Zocor) in healthy human volunteers. Biopharmaceutics and Drug Disposition 24(5): 183-189

Zhou, Q.; Ruan, Z.-R.; Yuan, H.; Jiang, B.; Xu, D.-H. 2006: Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. World Journal of Gastroenterology 12(17): 2742-2748

Lotti, M. 2003: Pharmacokinetics and blood levels of polychlorinated biphenyls. Toxicological Reviews 22(4): 203-215

Le Coutre, P.; Kreuzer, K.-A.; Pursche, S.; Bonin, M.v.; Leopold, T.; Baskaynak, G.ök.; Dörken, B.; Ehninger, G.; Ottmann, O.; Jenke, A.; Bornhäuser, M.; Schleyer, E. 2004: Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer ChemoTherapy and Pharmacology 53(4): 313-323

Jackson, D.L.; Milgrom, P.; Heacox, G.A.; Kharasch, E.D. 2006: Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers. Journal of Clinical Psychopharmacology 26(1): 4-8

Xiao, J.; Horst, S.; Hinkle, G.; Cao, X.; Kocak, E.; Fang, J.; Young, D.; Khazaeli, M.; Agnese, D.; Sun, D.; Martin, E. 2005: Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer BioTherapy and Radiopharmaceuticals 20(1): 16-26

Hitzenberger, G.; Strolin Benedetti, M.; Jannuzzo, M.G.; Silvestri, S.; Moro, E.; Frigerio, E.; Sassella, D. 1989: Pharmacokinetics and clinical tolerability of FCE 22101, a new penem antibiotic, in healthy volunteers after a single I.m. administration. Journal of ChemoTherapy 1(4 Suppl): 513-514

Ternant, D.; Paintaud, G. 2005: Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opinion on Biological Therapy 5(Suppl 1): S37-S47

Kambia, N.K.; Dine, T.; Odou, P.; Bah, S.; Azar, R.; Gressier, B.; Dupin-Spriet, T.ér.ès.; Luyckx, M.; Brunet, C. 2004: Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. European Journal of Drug Metabolism and Pharmacokinetics 29(4): 225-230

Novakova, K.; Laznicek, M.; Rypacek, F.; Machova, L. 2003: Pharmacokinetics and distribution of 125I-PLA-b-PEO block copolymers in rats. Pharmaceutical Development and Technology 8(2): 153-161

Darwish, M.; Tempero, K.; Kirby, M.; Thompson, J. 2005: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clinical Pharmacokinetics 44(12): 1279-1286

Kraeber-Bodéré, F.ço.; Faivre-Chauvet, A.; Ferrer, L.; Vuillez, J.-P.; Brard, P.-Y.; Rousseau, C.; Resche, I.; Devillers, A.; Laffont, S.; Bardiès, M.; Chang, K.; Sharkey, R.M.; Goldenberg, D.M.; Chatal, J.-F.ço.; Barbet, J. 2003: Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase i radioimmunotherapy trial. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 9(10 Part 2): 3973s-3981s

Kearney, B.P.; Yale, K.; Shah, J.; Zhong, L.; Flaherty, J.F. 2006: Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clinical Pharmacokinetics 45(11): 1115-1124

Hirata, S. 2004: Pharmacokinetics and drug dosage adjustment theory in patients undergoing renal replacement therapy. Nihon Rinsho. Japanese Journal of Clinical Medicine 62(Suppl 5): 55-64

Wang, J.-S.; DeVane, C.L. 2003: Pharmacokinetics and drug interactions of the sedative hypnotics. Psychopharmacology Bulletin 37(1): 10-29

Mannino, C.A.; South, S.M.; Inturrisi, C.E.; Quinones-Jenab, V. 2005: Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. Journal of Pain 6(12): 809-816

Jahnke, K.; Wagner, T.; Bechrakis, N.E.; Willerding, G.; Coupland, S.E.; Fischer, L.; Thiel, E.; Korfel, A. 2005: Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology 16(12): 1974-1978

Hiraga, Y.; Yuhki, Y.; Itoh, K.; Tadano, K.; Takahashi, Y.; Mukai, M. 2004: Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis. Modern Rheumatology 14(2): 135-142

Zherdev, V.P.; Voronina, T.A.; Garibova, T.L.; Kolyvanov, G.B.; Litvin, A.A.; Sariev, A.K.; Tokhmakhchi, V.N.; Vasil'ev, A.E. 2003: Pharmacokinetics and efficacy of phenazepam after transdermal and enteral administration in rats. Eksperimental'naia i Klinicheskaia Farmakologiia 66(1): 50-53

Bösenberg, A.T.; Thomas, J.; Cronje, L.; Lopez, T.; Crean, P.M.; Gustafsson, U.; Huledal, G.; Larsson, L.E. 2005: Pharmacokinetics and efficacy of ropivacaine for continuous epidural infusion in neonates and infants. Paediatric Anaesthesia 15(9): 739-749

Brenneisen, R.; Elsohly, M.A.; Murphy, T.P.; Passarelli, J.; Russmann, S.; Salamone, S.J.; Watson, D.E. 2004: Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. Journal of Analytical Toxicology 28(8): 625-630

Sarno, M.J.; Bell, J.; Edelman, S.V. 2002: Pharmacokinetics and glucodynamics of rapid-, short-, and intermediate-acting insulins: comparison of jet injection to needle syringe. Diabetes Technology and Therapeutics 4(6): 863-866

Van Herpen, C.M.; Huijbens, R.; Looman, M.; De Vries, J.; Marres, H.; Van De Ven, J.; Hermsen, R.; Adema, G.J.; De Mulder, P.H. 2003: Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 9(8): 2950-2956

Tran, H.; Petropoulos, D.; Worth, L.; Mullen, C.A.; Madden, T.; Andersson, B.; Choroszy, M.; Nguyen, J.; Webb, S.K.; Chan, K.W. 2004: Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 10(11): 805-812

Sternieri, E.; Coccia, C.P.R.; Pinetti, D.; Ferrari, A. 2006: Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments. Expert Opinion on Drug Metabolism and Toxicology 2(6): 961-979

Sternieri, E.; Coccia, C.P.R.; Pinetti, D.; Guerzoni, S.; Ferrari, A. 2006: Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opinion on Drug Metabolism and Toxicology 2(6): 981-1007

Boselli, E.; Breilh, D.; Rimmelé, T.; Djabarouti, S.; Toutain, J.ér.ôm.; Chassard, D.; Saux, M.-C.; Allaouchiche, B. 2005: Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Critical Care Medicine 33(7): 1529-1533

Boselli, E.; Breilh, D.; Rimmelé, T.; Djabarouti, S.; Saux, M.-C.; Chassard, D.; Allaouchiche, B. 2005: Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Critical Care Medicine 33(1): 104-109

Boselli, E.; Breilh, D.; Saux, M.-C.; Gordien, J.-B.; Allaouchiche, B. 2006: Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Medicine 32(12): 2059-2062

Toyohara, J.; Gogami, A.; Hayashi, A.; Yonekura, Y.; Fujibayashi, Y. 2003: Pharmacokinetics and metabolism of 5-125I-iodo-4'-thio-2'-deoxyuridine in rodents. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 44(10): 1671-1676

Jannuzzo, M.G.; Vaiani, R.; Strolin Benedetti, M.; Carnovali, M.; Cassinelli, G.; Corigli, R. 1989: Pharmacokinetics and metabolism of FCE 22101, a new penem antibiotic. Journal of ChemoTherapy 1(4 Suppl): 511-512

Tsuda-Tsukimoto, M.; Ogasawara, Y.; Kume, T. 2005: Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 35(4): 373-389

Lin, C.-C.; Yeh, L.-T.; Luu, T.; Lourenco, D.; Lau, J.Y.N. 2003: Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. Antimicrobial Agents and ChemoTherapy 47(4): 1395-1398

Cook, C.S.; Berry, L.M.; Bible, R.H.; Hribar, J.D.; Hajdu, E.; Liu, N.W. 2003: Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metabolism and Disposition: the Biological Fate of Chemicals 31(11): 1448-1455

Lin, C.-C.; Luu, K.; Lourenco, D.; Yeh, L.-T. 2003: Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. Antimicrobial Agents and ChemoTherapy 47(8): 2458-2463

Wu, D.; Wu, Z.; Yang, J.; Nair, V.A.; Miller, D.D.; Dalton, J.T. 2006: Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study. Drug Metabolism and Disposition: the Biological Fate of Chemicals 34(3): 483-494

Dahlin, D.C.; Rahimy, M.H. 2007: Pharmacokinetics and metabolism of anecortave acetate in animals and humans. Survey of Ophthalmology 52(Suppl 1): S49-S61

Moise, P.A.; Birmingham, M.C.; Schentag, J.J. 2000: Pharmacokinetics and metabolism of moxifloxacin. Drugs of Today 36(4): 229-244

Huestis, M.A. 2005: Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handbook of Experimental Pharmacology 168: 657-690

Radhofer-Welte, S. 1999: Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man. Drugs of Today 35(10): 765-772

Bourgeois, B.F. 1999: Pharmacokinetics and metabolism of topiramate. Drugs of Today 35(1): 43-48

Jones, P.; Atack, J.R.; Braun, M.P.; Cato, B.P.; Chambers, M.S.; O'Connor, D.; Cook, S.M.; Hobbs, S.C.; Maxey, R.; Szekeres, H.J.; Szeto, N.; Wafford, K.A.; MacLeod, A.M. 2006: Pharmacokinetics and metabolism studies on (3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine, a functionally selective GABA(A) alpha5 inverse agonist for cognitive dysfunction. Bioorganic and Medicinal Chemistry Letters 16(4): 872-875

Gao, H.-m.; Wang, Z.-m.; Tian, J. 2005: Pharmacokinetics and metabolites of scutellarin in normal and model rats. Yao Xue Xue Bao 40(11): 1024-1027

Marín, P.; Cárceles, C.M.; Escudero, E.; Fernández-Varón, E. 2007: Pharmacokinetics and milk penetration of ibafloxacin after intravenous administration to lactating goats. Canadian Journal of Veterinary Research 71(1): 74-76

Sojan, S.M.; Smyth, D.R.; Tsopelas, C.; Mudge, D.; Collins, P.J.; Chatterton, B.E. 2005: Pharmacokinetics and normal scintigraphic appearance of 99mTc aprotinin. Nuclear Medicine Communications 26(6): 535-539

Königsson, K.; Törneke, K.; Engeland, I.V.; Odensvik, K.; Kindahl, H. 2003: Pharmacokinetics and pharmacodynamic effects of flunixin after intravenous, intramuscular and oral administration to dairy goats. Acta Veterinaria Scandinavica 44(3-4): 153-159

Krähenbühl, S. 2004: Pharmacokinetics and pharmacodynamices in the elderly. Praxis 93(33): 1305-1310

Eiseman, J.L.; Lan, J.; Lagattuta, T.F.; Hamburger, D.R.; Joseph, E.; Covey, J.M.; Egorin, M.J. 2005: Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer ChemoTherapy and Pharmacology 55(1): 21-32

Curtis, L.D.; Brown, A.; Comer, M.B.; Senior, J.M.; Warrington, S.; Dawson, K.M. 2005: Pharmacokinetics and pharmacodynamics of BB-10153, a thrombin-activatable plasminogen, in healthy volunteers. Journal of Thrombosis and Haemostasis: Jth 3(6): 1180-1186

Almeida, L.; Soares-da-Silva, P.íc. 2003: Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans. Drugs in R&d 4(4): 207-217

Graefe-Mody, E.U.; Schühly, U.; Rathgen, K.; Stähle, H.; Leitner, J.M.; Jilma, B. 2006: Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. Journal of Thrombosis and Haemostasis: Jth 4(7): 1502-1509

Galenko-Yaroshevskii, A.P.; Derlugov, L.P.; Ponomarev, V.V.; Dukhanin, A.S. 2003: Pharmacokinetics and pharmacodynamics of a new local anesthetic agent. Bulletin of Experimental Biology and Medicine 136(2): 170-173

Waller, E.K.; Langston, A.A.; Lonial, S.; Cherry, J.; Somani, J.; Allen, A.J.; Rosenthal, H.; Redei, I. 2003: Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 9(7): 460-471

Andes, D. 2006: Pharmacokinetics and pharmacodynamics of antifungals. Infectious Disease Clinics of North America 20(3): 679-697

Talbert, R.L. 2004: Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Failure Reviews 9(2): 131-137

Tahara, K.; Saigusa, K.; Kagawa, Y.; Taguchi, M.; Hashimoto, Y. 2006: Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure. Drug Metabolism and Pharmacokinetics 21(5): 389-394

Johnston, A.J.; Steiner, L.A.; O'Connell, M.; Chatfield, D.A.; Gupta, A.K.; Menon, D.K. 2004: Pharmacokinetics and pharmacodynamics of dopamine and norepinephrine in critically ill head-injured patients. Intensive Care Medicine 30(1): 45-50

Jackson, A.; Taylor, S.; Boffito, M. 2004: Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors. Aids Reviews 6(4): 208-217

Haas, C.E.; Nelsen, J.L.; Raghavendran, K.; Mihalko, W.; Beres, J.; Ma, Q.; Forrest, A. 2005: Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. Journal of Trauma 59(6): 1336-1343; Discussion: 1343-1344

Mayer, M.D.; Khosravan, R.; Vernillet, L.; Wu, J.-T.; Joseph-Ridge, N.; Mulford, D.J. 2005: Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. American Journal of Therapeutics 12(1): 22-34

Raybon, J.J.; Boje, K.M.K. 2007: Pharmacokinetics and pharmacodynamics of gamma-hydroxybutyric acid during tolerance in rats: effects on extracellular dopamine. Journal of Pharmacology and Experimental Therapeutics 320(3): 1252-1260

Peng, B.; Hayes, M.; Resta, D.; Racine-Poon, A.; Druker, B.J.; Talpaz, M.; Sawyers, C.L.; Rosamilia, M.; Ford, J.; Lloyd, P.; Capdeville, R. 2004: Pharmacokinetics and pharmacodynamics of imatinib in a phase i trial with chronic myeloid leukemia patients. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 22(5): 935-942

Leary, A.C.; Stote, R.M.; Breedt, H.J.; O'Brien, J.; Buckley, B. 2005: Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses. Diabetes Technology and Therapeutics 7(1): 124-130

Leary, A.C.; Stote, R.M.; Cussen, K.; O'Brien, J.; Leary, W.P.; Buckley, B. 2006: Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: a preliminary study. Diabetes Technology and Therapeutics 8(1): 81-88

Murakami, M.; Furuie, H.; Matsuguma, K.; Wanibuchi, A.; Kikawa, S.; Irie, S. 2005: Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting beta1-selective blocker, in a dose escalation regimen in healthy male volunteers. Drug Metabolism and Pharmacokinetics 20(5): 337-344

Gremse, D.; Winter, H.; Tolia, V.; Gunasekaran, T.; Pan, W.-J.; Karol, M.; Chiu, Y.-L.; Pilmer, B.; Book, L. 2002: Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition 35(Suppl 4): S319-S326

Sánchez Navarro, A.; Colino Gandarillas, C.-I.; Alvarez Lerma, F.; Menacho, Y.A.; Domínguez-Gil, A. 2005: Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients. Clinical Pharmacokinetics 44(6): 627-635

Czock, D.; Aisenpreis, U.; Rasche, F.M.; Jehle, P.M. 2003: Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 41(10): 492-497

Millán, O.; Brunet, M.è; Martorell, J.; García, F.; Vidal, E.; Rojo, I.; Plana, M.; Gallart, T.; Pumarola, T.; Miró, J.M.; Gatell, J.M. 2005: Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. Clinical Pharmacokinetics 44(5): 525-538

Auret, K.; Roger Goucke, C.; Ilett, K.F.; Page-Sharp, M.; Boyd, F.; Oh, T.E. 2006: Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. Therapeutic Drug Monitoring 28(3): 359-366

Sica, D.A. 2005: Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Failure Reviews 10(1): 23-29

Mori, M.; Nishi, S.; Asada, A. 2004: Pharmacokinetics and pharmacodynamics of olprinone after cardiac surgery. Osaka City Medical Journal 50(1): 1-8

Vincent, J.-L.; Spapen, H.D.M.H.; Creteur, J.; Piagnerelli, M.; Hubloue, I.; Diltoer, M.; Roman, A.; Stevens, E.; Vercammen, E.; Beaver, J.S. 2006: Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. Critical Care Medicine 34(6): 1661-1667

Edick, M.J.; Gajjar, A.; Mahmoud, H.H.; van de Poll, M.E.C.; Harrison, P.L.; Panetta, J.C.; Rivera, G.K.; Ribeiro, R.C.; Sandlund, J.T.; Boyett, J.M.; Pui, C.-H.; Relling, M.V. 2003: Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 21(7): 1340-1346

Gandhi, V.; Kantarjian, H.; Faderl, S.; Bonate, P.; Du, M.; Ayres, M.; Rios, M.B.; Keating, M.J.; Plunkett, W. 2003: Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 9(17): 6335-6342

Egan, T.D. 2000: Pharmacokinetics and pharmacodynamics of remifentanil: an update in the year 2000. Current Opinion in Anaesthesiology 13(4): 449-455

Kirchheiner, J.; Thomas, S.; Bauer, S.; Tomalik-Scharte, D.; Hering, U.; Doroshyenko, O.; Jetter, A.; Stehle, S.; Tsahuridu, M.; Meineke, I.; Brockmöller, Jürgen.; Fuhr, U. 2006: Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clinical Pharmacology and Therapeutics 80(6): 657-667

Barbot, A.; Venisse, N.; Rayeh, F.; Bouquet, S.; Debaene, B.; Mimoz, O. 2003: Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Medicine 29(9): 1528-1534

Czock, D.; Keller, F.; Rasche, F.M.; Häussler, U. 2005: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clinical Pharmacokinetics 44(1): 61-98

Dieterle, W.; Mann, J.; Kutz, K. 2004: Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects. Journal of Clinical Pharmacology 44(1): 59-66

Wernevik, L.C.; Nyström, P.; Johnsson, G.; Nakanishi, T.; Eriksson, U.G. 2006: Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men. Clinical Pharmacokinetics 45(1): 77-84

Lahlou, N. 2005: Pharmacokinetics and pharmacodynamics of triptorelin. Annales d'Urologie 39(Suppl 3): S78-S84

Nomura, T. 1992: Pharmacokinetics and pharmacodynamics of vecuronium bromide. Journal of Anesthesia 6(1): 28-37

Hidalgo, M.; Bloedow, D. 2003: Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). Seminars in Oncology 30(3 Suppl 7: 25-33

Clark, S.M.; Saade, G.R.; Snodgrass, W.R.; Hankins, G.D.V. 2006: Pharmacokinetics and pharmacotherapy of thionamides in pregnancy. Therapeutic Drug Monitoring 28(4): 477-483

Aumais, G.; Lefebvre, M.; Massicotte, J.; Tremblay, C.; Kasbo, J.; Brunet, J.-S.éb.; Cardinal, C.; Grace, M.; Spénard, J. 2005: Pharmacokinetics and pilot efficacy of a mesalazine rectal gel in distal ulcerative colitis. Drugs in R&d 6(1): 41-46

Li, T.; Pang, Y.; Wang, Z.; Jia, Y.; Cheng, Q.; Sun, J. 2003: Pharmacokinetics and relative bioavailability of KC-404 sustained release tablets in healthy volunteers. Sichuan da Xue Xue Bao. Yi Xue Ban 34(3): 541-543

Zhang, Z.; Chen, B.-l.; Wang, K.; Huang, Y.-l.; Fang, S.-q.; Gu, D.-l.; Fang, L.; Han, S.-j. 2002: Pharmacokinetics and relative bioavailability of probucol inclusion complex capsule in healthy dogs. Yao Xue Xue Bao 37(3): 210-213

Li, J.S.; Sanders, S.P.; Perry, A.E.; Stinnett, S.S.; Jaggers, J.; Bokesch, P.; Reynolds, L.; Nassar, R.; Anderson, P.A.W. 2004: Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. American Heart Journal 147(1): 173-180

Barrett, R.J.; Lamson, M.J.; Johnson, J.; Smith, W.B. 2005: Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. Journal of Nuclear Cardiology: Official Publication of the American Society of Nuclear Cardiology 12(2): 166-171

Brown, S.A.; Lipschitz, A.H.; Kenkel, J.M.; Sorokin, E.; Shepherd, G.; Grebe, S.; Oliver, L.K.; Luby, M.; Rohrich, R.J. 2004: Pharmacokinetics and safety of epinephrine use in liposuction. Plastic and Reconstructive Surgery 114(3): 756

Dutta, S.; Reed, R.C.; Cavanaugh, J.H. 2004: Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 61(21): 2280-2283

Chow, H.-H.S.; Cai, Y.; Hakim, I.A.; Crowell, J.A.; Shahi, F.; Brooks, C.A.; Dorr, R.T.; Hara, Y.; Alberts, D.S. 2003: Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon e in healthy individuals. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 9(9): 3312-3319

Kenkel, J.M.; Lipschitz, A.H.; Shepherd, G.; Armstrong, V.W.; Streit, F.; Oellerich, M.; Luby, M.; Rohrich, R.J.; Brown, S.A. 2004: Pharmacokinetics and safety of lidocaine and monoethylglycinexylidide in liposuction: a microdialysis study. Plastic and Reconstructive Surgery 114(2): 516

Hayes, K.C.; Potter, P.J.; Hsieh, J.T.; Katz, M.A.; Blight, A.R.; Cohen, R. 2004: Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Archives of Physical Medicine and Rehabilitation 85(1): 29-34

Bichler, J.; Spycher, M.O.; Amstutz, H.-P.; Andresen, I.; Gaede, K.; Miescher, S. 2004: Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers. Transfusion Medicine 14(2): 165-171

Wang, L.H.; Wiznia, A.A.; Rathore, M.H.; Chittick, G.E.; Bakshi, S.S.; Emmanuel, P.J.; Flynn, P.M. 2004: Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrobial Agents and ChemoTherapy 48(1): 183-191

Babalola, C.P.; Oladimeji, F.A.; Femi-Oyewo, M.N. 2004: Pharmacokinetics and saliva secretion of paracetamol in healthy male Nigerians. West African Journal of Medicine 23(1): 10-14

Laliberte, K.; Arneson, C.; Jeffs, R.; Hunt, T.; Wade, M. 2004: Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. Journal of Cardiovascular Pharmacology 44(2): 209-214

Wang, X.-y.; Yang, L.; Cheng, Y.-h. 2004: Pharmacokinetics and targeting characteristics of adriamycin after canine hepatic arterial embolization with adriamycin-lipiodol emulsion. Di 1 Jun Yi da Xue Xue Bao 24(12): 1428-1430

Hayakawa, M.; Ito, Y.; Fujita, I.; Iseki, K.; Gando, S. 2006: Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study. Asaio Journal 52(4): 398-403

Tomson, T.ör.; Battino, D. 2007: Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clinical Pharmacokinetics 46(3): 209-219

Preskorn, S.H. 2005: Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clinical Pharmacokinetics 44(11): 1117-1133

Anderton, M.J.; Manson, M.M.; Verschoyle, R.D.; Gescher, A.; Lamb, J.H.; Farmer, P.B.; Steward, W.P.; Williams, M.L. 2004: Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 10(15): 5233-5241

Li, C.-Q.; He, L.-C.; Deng, T. 2006: Pharmacokinetics and tissue distribution of atractylenolide IIi in rats. Zhong Yao Cai 29(8): 807-809

Wu, G.; Meng, Y.; Zhu, X.; Huang, C. 2006: Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. Analytical Biochemistry 358(1): 25-30

Sova, P.; Chladek, J.; Zak, F.; Mistr, A.; Kroutil, A.; Semerad, M.; Slovak, Z. 2005: Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV). International Journal of Pharmaceutics 288(1): 123-129

Von Hentig, N.; Müller, A.; Rottmann, C.; Lutz, T.; Klauke, S.; Kurowski, M.; Staszewski, S.; Harder, S. 2006: Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults. European Journal of Medical Research 11(6): 236-244

Ballow, M.; Berger, M.; Bonilla, F.A.; Buckley, R.H.; Cunningham-Rundles, C.H.; Fireman, P.; Kaliner, M.; Ochs, H.D.; Skoda-Smith, S.; Sweetser, M.T.; Taki, H.; Lathia, C. 2003: Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sanguinis 84(3): 202-210

Beer, T.M.; Javle, M.; Lam, G.N.; Henner, W.D.; Wong, A.; Trump, D.L. 2005: Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 11(21): 7794-7799

Kielstein, J.T.; Czock, D.; Schöpke, T.; Hafer, C.; Bode-Böger, S.M.; Kuse, E.; Keller, F.; Fliser, D. 2006: Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Critical Care Medicine 34(1): 51-56

Hurria, A.; Fleming, M.T.; Baker, S.D.; Kelly, W.K.; Cutchall, K.; Panageas, K.; Caravelli, J.; Yeung, H.; Kris, M.G.; Gomez, J.; Miller, V.A.; D'Andrea, G.; Scher, H.I.; Norton, L.; Hudis, C. 2006: Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 12(20 Part 1): 6100-6105

Chinn, P.C.; Morena, R.A.; Santoro, D.A.; Kazules, T.; Kashmiri, S.V.S.; Schlom, J.; Hanna, N.; Braslawsky, G. 2006: Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft. Cancer BioTherapy and Radiopharmaceuticals 21(2): 106-116

Brouwers, A.; Mulders, P.; Oosterwijk, E.; Buijs, W.; Corstens, F.; Boerman, O.; Oyen, W. 2004: Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. Cancer BioTherapy and Radiopharmaceuticals 19(4): 466-477

Danielson, B.G.; Beshara, S. 2003: Pharmacokinetics and utilization of iron sucrose. American journal of kidney diseases: the official journal of the National Kidney Foundation 42(5): 1104; author reply 1104-5

Hummel, M.; Yonan, N.; Ross, H.; Miller, L.W.; Sechaud, R.; Balez, S.; Koelle, E.U.; Gerosa, G. 2007: Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clinical Transplantation 21(1): 18-23

Dettli, L. 1963: Pharmacokinetics as a methodological problem in basic medical education. I. Basis and capacity constants. Arzneimittel-Forschung 13: 151-155

Dettli, L. 1963: Pharmacokinetics as a methodological problem in basic medical training. 2. Rate constants. Arzneimittel-Forschung 13: 509-512

Fleischhack, G.; Jaehde, U.; Bode, U. 2005: Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clinical Pharmacokinetics 44(1): 1-31

Crome, P. 2005: Pharmacokinetics in older people. Experimental Lung Research 31(Suppl 1): 80-83

Cusack, B.J. 2004: Pharmacokinetics in older persons. American Journal of Geriatric PharmacoTherapy 2(4): 274-302

De Maar, E.W. 1955: Pharmacokinetics in parkinsonism. Geneeskundige Gids 33(17): 339-348

Kelsey, M.C. 1989: Pharmacokinetics in the elderly with reference to the oral prodrug cefuroxime axetil. Journal of ChemoTherapy 1(4 Suppl): 517-518

Alcorn, J.; McNamara, P.J. 2003: Pharmacokinetics in the newborn. Advanced Drug Delivery Reviews 55(5): 667-686

Song, M.; Qian, W.; Hang, T.-J.; Zhang, Z.-X. 2005: Pharmacokinetics of (-)-clausenamide and its major metabolite 6-hydroxyl-clausenamide in beagle dogs by HPLC/MS. Yao Xue Xue Bao 40(10): 940-944

Shin, B.S.; Kim, C.H.; Lee, M.-N.; Hur, M.-W.; Lee, K.C.; Youn, Y.S.; Yoo, S.D. 2007: Pharmacokinetics of 125I-GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, after intravenous, nasal, oral, and subcutaneous administration. Regulatory Peptides 140(1-2): 74-80

Lee, J.; Lee, J.; Yoon, S.; Nho, K. 2006: Pharmacokinetics of 125I-radiolabelled PEG-hemoglobin SB1. Artificial Cells Blood Substitutes and Immobilization Biotechnology 34(3): 277-292

Rudek, M.A.; Zhao, M.; He, P.; Hartke, C.; Gilbert, J.; Gore, S.D.; Carducci, M.A.; Baker, S.D. 2005: Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23(17): 3906-3911

Kim, E.J.; Chung, M.Y.; Chung, H.J.; Son, M.W.; Kwon, J.W.; Yoo, M.; Lee, M.G. 2006: Pharmacokinetics of 7-carboxymethyloxy-3',4',5-trimethoxy flavone (DA-6034), a derivative of flavonoid, in mouse and rat models of chemically-induced inflammatory bowel disease. Journal of Pharmacy and Pharmacology 58(1): 27-35

Du, Y.; Zhang, Q.; Chen, G.G.; Wei, P.; Tu, C.Y. 2005: Pharmacokinetics of Astragaloside IV in rats by liquid chromatography coupled with tandem mass spectrometry. European Journal of Drug Metabolism and Pharmacokinetics 30(4): 269-273

Weinz, C.; Buetehorn, U.; Daehler, H-P.; Kohlsdorfer, C.; Pleiss, U.; Sandmann, S.; Schlemmer, K-H.; Schwarz, T.; Steinke, W. 2005: Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 35(9): 891-910

Liu, Y.-P.; Li, Q.-S.; Huang, Y.-R.; Zhou, M.-J.; Liu, C.-X. 2005: Pharmacokinetics of C-1027 in mice as determined by TCA-RA method. World Journal of Gastroenterology 11(5): 717-720

Salt, A.N. 2005: Pharmacokinetics of Drug Entry into Cochlear Fluids. Volta Review 105(3): 277-298

González-Esquivel, D.F.; Pérez, R.M.; Cook, H.J. 2004: Pharmacokinetics of HEPP, a new anticonvulsant, in healthy subjects and rabbits after multiple doses. Biopharmaceutics and Drug Disposition 25(2): 85-90

Neville, K.; Blaney, S.; Bernstein, M.; Thompson, P.; Adams, D.; Aleksic, A.; Berg, S. 2004: Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 10(15): 5072-5075

Hirata, K.; Horikoshi, N.; Tominaga, K.; Sohma, K.; Yamaguchi, K.; Okazaki, M.; Furuhata, T.; Sasaki, K.; Nakano, Y.; Ishizuka, H.; Yamada, Y.; Uno, S.; Taguchi, T.; Yamamitsu, S.; Shirasaka, T. 2006: Pharmacokinetics of S-1. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(Suppl 1): 27-35

Kearbey, J.D.; Wu, D.; Gao, W.; Miller, D.D.; Dalton, J.T. 2004: Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 34(3): 273-280

Takizawa, Y.; Nishimura, H.; Morota, T.; Tomisawa, H.; Takeda, S.; Aburada, M. 2004: Pharmacokinetics of TJ-8117 (Onpi-to), a drug for renal failure (I): Plasma concentration, distribution and excretion of [3H]-(-)epicatechin 3-O-gallate in rats and dogs. European Journal of Drug Metabolism and Pharmacokinetics 29(2): 91-101

Wilkins, E. 2004: Pharmacokinetics of Telzir (fosamprenavir). Journal of HIV Therapy 9(4): 87-91

Cheung, W.K.; Greene, D.S.; Kuye, O.; Shin, K.; Tonelli, A.P.; Houston, A.; Hibberd, M.; Faulkner, R.D.; Silber, B.M. 1989: Pharmacokinetics of YTR830H and piperacillin after intravenous coadministration. Journal of ChemoTherapy 1(4 Suppl): 507-508

Cheung, W.K.; Greene, D.S.; Kuye, O.; Smith, M.P.; Holder, A.; Fernandez, P.; Houston, A.; Faulkner, R.D.; Silber, B.M. 1989: Pharmacokinetics of YTR830H in healthy human subjects. Journal of ChemoTherapy 1(4 Suppl): 505-506

Fernández-Varón, E.; Cárceles, C.M.; Espuny, A.; Marín, P.; Escudero, E. 2004: Pharmacokinetics of a combination preparation of ampicillin and sulbactam in turkeys. American Journal of Veterinary Research 65(12): 1658-1663

Rayburn, W.F.; Powers, B.L.; Plasse, T.F.; Carr, D.; Di Spirito, M. 2006: Pharmacokinetics of a controlled-release misoprostol vaginal insert at term. Journal of the Society for Gynecologic Investigation 13(2): 112-117

Chik, Z.; Johnston, A.; Tucker, A.T.; Chew, S.L.; Michaels, L.; Alam, C.A.S. 2006: Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. British Journal of Clinical Pharmacology 61(3): 275-279

Choi, J.H.; Dresler, C.M.; Norton, M.R.; Strahs, K.R. 2003: Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine and Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco 5(5): 635-644

Van der Lee, M.; Verweel, G.; de Groot, R.; Burger, D. 2006: Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. Antiviral Therapy 11(4): 439-445

Kletzel, M.; Jacobsohn, D.; Duerst, R. 2006: Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 12(4): 472-479

Villar, A.; Aronis, S.; Morfini, M.; Santagostino, E.; Auerswald, G.; Thomsen, H.F.; Erhardtsen, E.; Giangrande, P.L.F. 2004: Pharmacokinetics of activated recombinant coagulation factor VIi (NovoSeven) in children vs. adults with haemophilia a. Haemophilia: the Official Journal of the World Federation of Hemophilia 10(4): 352-359

Lin, J.H.; Russell, G.; Gertz, B. 1999: Pharmacokinetics of alendronate: an overview. International Journal of Clinical Practice. Suppl 101: 18-26

Takitani, K.; Nagai, K.; Kanbe, E.; Inoue, A.; Kawakami, C.; Kuno, T.; Tamai, H. 2003: Pharmacokinetics of all-trans retinoic acid in acute promyelocytic leukemia patients on dialysis. American Journal of Hematology 74(2): 147-148

Takitani, K.; Koh, M.; Inoue, A.; Kawakami, C.; Kuno, T.; Tamai, H. 2006: Pharmacokinetics of all-trans retinoic acid in adults and children with acute promyelocytic leukemia. American Journal of Hematology 81(9): 720-721

Vidal Pla, R.; Padullés Zamora, N.úr.; Sala Piñol, F.; Jardí Margaleff, R.; Rodríguez Frías, F.; Montoro Ronsano, J.é B. 2006: Pharmacokinetics of alpha1-antitrypsin replacement therapy in severe congenital emphysema. Archivos de Bronconeumologia 42(10): 553-556

Yang, R.-H.; Rong, X.-Z.; Zhang, T.; Hua, R. 2007: Pharmacokinetics of amikacin in the subeschar tissue fluid following severe burns. Nan Fang Yi Ke da Xue Xue Bao 27(2): 172-174

Golovenko, N.Y.; Borisyuk, I.Y. 2005: Pharmacokinetics of amixin after repeated peroral administration to mice. Bulletin of Experimental Biology and Medicine 140(6): 708-710

Kovarik, J.M.; Kaplan, B.; Silva, H.él.T.; Kahan, B.D.; Dantal, J.; McMahon, L.; Berthier, S.; Hsu, C.-H.; Rordorf, C. 2003: Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 3(5): 606-613

Glue, P.; Fang, A.; Gandelman, K.; Klee, B. 2006: Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers. American Journal of Therapeutics 13(5): 418-422

Yang, B-Bing.; Baughman, S.; Sullivan, J.T. 2003: Pharmacokinetics of anakinra in subjects with different levels of renal function. Clinical Pharmacology and Therapeutics 74(1): 85-94

Tomaselli, F.; Maier, A.; Smolle-Jüttner, F.-M. 2003: Pharmacokinetics of antibiotics in inflamed and healthy lung tissue. Wiener Medizinische Wochenschrift 153(15-16): 342-344

Fraaij, P.L.A.; van Kampen, J.J.A.; Burger, D.M.; de Groot, R. 2005: Pharmacokinetics of antiretroviral therapy in HIV-1-infected children. Clinical Pharmacokinetics 44(9): 935-956

King, J.R.; Yogev, R.; Aldrovandi, G.; Chadwick, E.; Acosta, E.P. 2004: Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube. HIV Clinical Trials 5(5): 288-293

Mirochnick, M.; Capparelli, E. 2004: Pharmacokinetics of antiretrovirals in pregnant women. Clinical Pharmacokinetics 43(15): 1071-1087

Baillie, G.M. 2005: Pharmacokinetics of antiviral agents for the treatment of cytomegalovirus infection. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 62(8 Suppl 1: S14-S17

Lau, Y.Y.; Okochi, H.; Huang, Y.; Benet, L.Z. 2006: Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metabolism and Disposition: the Biological Fate of Chemicals 34(7): 1175-1181

Teramoto, T.; Fukao, T.; Tomita, Y.; Terauchi, Y.; Hosoi, K.; Matsui, E.; Aoki, M.; Kondo, N.; Mikawa, H. 2006: Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system in Japanese children with bronchial asthma. Allergology International: Official Journal of the Japanese Society of Allergology 55(3): 317-320

Wu, H.-b.; Fang, Y.-q. 2004: Pharmacokinetics of beta-asarone in rats. Yao Xue Xue Bao 39(10): 836-838

Moss, T.J.M.; Doherty, D.A.; Nitsos, I.; Harding, R.; Newnham, J.P. 2003: Pharmacokinetics of betamethasone after maternal or fetal intramuscular administration. American Journal of Obstetrics and Gynecology 189(6): 1751-1757

Liu, Q.; Luo, G.; Wang, Y.; Ma, Y.; Zhang, R. 2005: Pharmacokinetics of breviscapine in dogs and rabbits following single intravenous administration. Zhong Yao Cai 28(10): 913-916

Koyama, K.; Shimazu, Y.; Kikuno, T.; Kaziwara, H.; Sekiguti, H. 2003: Pharmacokinetics of bromazepam in 57 patients with acute drug intoxication. Chudoku Kenkyu: Chudoku Kenkyukai Jun Kikanshi 16(1): 51-56

Edsbäcker, S.; Andersson, T. 2004: Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clinical Pharmacokinetics 43(12): 803-821

Davis, G.A.; Rudy, A.C.; Archer, S.M.; Wermeling, D.P. 2004: Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 61(3): 261-266

Camarasa, J.; Escubedo, E.; Adzet, T. 1988: Pharmacokinetics of caffeic acid in rats by a high-performance liquid chromatography method. Journal of Pharmaceutical and Biomedical Analysis 6(5): 503-510

Hamada, C.; Hayashi, K.; Shou, I.; Inaba, M.; Ro, Y.; Io, H.; Maeda, K.; Fukui, M.; Tomino, Y. 2005: Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 25(6): 570-575

McGilveray, I.J. 2005: Pharmacokinetics of cannabinoids. Pain Research and Management 10 Suppl A: 15a-22a

Imbs, J-Louis.; Welsch, M.; Lates, S. 2006: Pharmacokinetics of cardiovascular drugs in the elderly. Bulletin del'Academie Nationale de Medecine 190(4-5): 843

Booranalertpaisarn, V.; Eiam-Ong, S.; Wittayalertpanya, S.; Kanjanabutr, T.; Na Ayudhya, D.P. 2003: Pharmacokinetics of ceftazidime in CAPD-related peritonitis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 23(6): 574-579

Tan, A.R.; Moore, D.F.; Hidalgo, M.; Doroshow, J.H.; Poplin, E.A.; Goodin, S.; Mauro, D.; Rubin, E.H. 2006: Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 12(21): 6517-6522

Hurria, A.; Lichtman, S.M. 2007: Pharmacokinetics of chemotherapy in the older patient. Cancer Control: Journal of the Moffitt Cancer Center 14(1): 32-43

Wagenlehner, F.M.E.; Kinzig-Schippers, M.; Tischmeyer, U.; Wagenlehner, C.; Sörgel, F.; Dalhoff, A.; Naber, K.G. 2006: Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. International Journal of Antimicrobial Agents 27(1): 7-14

Jacobson, M.A.; Nicolau, D.P.; Sutherland, C.; Smith, A.; Aweeka, F. 2005: Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. HIV Clinical Trials 6(5): 246-253

Li, J.; Rayner, C.R.; Nation, R.L.; Deans, R.; Boots, R.; Widdecombe, N.; Douglas, A.; Lipman, J. 2005: Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrobial Agents and ChemoTherapy 49(11): 4814-4815

Lambiase, A.; Tirassa, P.; Micera, A.; Aloe, L.; Bonini, S. 2005: Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats. Investigative Ophthalmology and Visual Science 46(10): 3800-3806

Liu, T.-z.; Qian, Z.-y. 2002: Pharmacokinetics of crocetin in rats. Yao Xue Xue Bao 37(5): 367-369

Pescovitz, M.D.; Bumgardner, G.; Gaston, R.S.; Kirkman, R.L.; Light, S.; Patel, I.H.; Nieforth, K.; Vincenti, F. 2003: Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clinical Transplantation 17(6): 511-517

Veal, G.J.; Cole, M.; Errington, J.; Parry, A.; Hale, J.; Pearson, A.D.J.; Howe, K.; Chisholm, J.C.; Beane, C.; Brennan, B.; Waters, F.; Glaser, A.; Hemsworth, S.; McDowell, H.; Wright, Y.; Pritchard-Jones, K.; Pinkerton, R.; Jenner, G.; Nicholson, J.; Elsworth, A.M.; Boddy, A.V. 2005: Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 11(16): 5893-5899

Heatherington, A.C.; Dittrich, C.; Sullivan, J.T.; Rossi, G.; Schueller, J. 2006: Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. Clinical Pharmacokinetics 45(2): 199-211

Huupponen, R.; Paija, O.; Salonen, M.; Björklund, H.; Rouru, J.; Anttila, M. 2003: Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. Drugs in R&d 4(6): 339-345

Lu, C.C.; Tsai, C.S.; Ho, S.T.; Chueng, C.M.; Wang, J.J.; Wong, C.S.; Chang, S.Y.; Lin, C.Y. 2004: Pharmacokinetics of desflurane uptake into the brain and body. Anaesthesia 59(3): 216-221

Pope, L.E.; Khalil, M.H.; Berg, J.E.; Stiles, M.; Yakatan, G.J.; Sellers, E.M. 2004: Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. Journal of Clinical Pharmacology 44(10): 1132-1142

Hasan, S.M.F.; Ahmed, T.; Talib, N.; Hasan, F. 2005: Pharmacokinetics of diclofenac sodium in normal man. Pakistan Journal of Pharmaceutical Sciences 18(1): 18-24

Roberts, D.M.; Southcott, E.; Potter, J.M.; Roberts, M.S.; Eddleston, M.; Buckley, N.A. 2006: Pharmacokinetics of digoxin cross-reacting substances in patients with acute yellow Oleander (Thevetia peruviana) poisoning, including the effect of activated charcoal. Therapeutic Drug Monitoring 28(6): 784-792

Lares-Asseff, I.; Juárez-Olguín, H.; Flores-Pérez, J.; Bobadilla-Chávez, J. 2004: Pharmacokinetics of digoxin in children with congestive heart failure aggravated by other diseases. Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 56(1): 32-37

Kondoh, T.; Nakashima, M.; Sasaki, H.; Moriuchi, H. 2005: Pharmacokinetics of donepezil in down syndrome. Annals of PharmacoTherapy 39(3): 572-573

Molina, J.-M.; Peytavin, G.; Perusat, S.; Lascoux-Combes, C.; Sereni, D.; Rozenbaum, W.; Chene, G. 2004: Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Medicine 5(2): 99-104

Bellibas, S.E.; Siddique, Z.; Dorr, A.; Bertasso, A.; Sista, P.; Kolis, S.J.; Cotler, S.; Delora, P. 2004: Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatric Infectious Disease Journal 23(12): 1137-1141

Argenti, D.; Hoppensteadt, D.; Heald, D.; Jensen, B.; Fareed, J. 2003: Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. American Journal of Therapeutics 10(4): 241-246

Ettenger, R.; Bartosh, S.; Choi, L.; Zhu, W.; Niederberger, W.; Campestrini, J.; Bastien, M.-C.; Schmouder, R. 2005: Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatric Transplantation 9(6): 780-787

Skorokhod, O.A.; Garmaeva, T.'y.T.; Vitvitsky, V.M.; Isaev, V.G.; Parovichnikova, E.N.; Savchenko, V.G.; Ataullakhanov, F.I. 2004: Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 10(4): Pi55-Pi64

Wang, L.-q.; Hu, Z.-y.; Yu, Q.; Guo, X.; Xiong, J.; Huang, Z.-z.; Cheng, Z.-n. 2005: Pharmacokinetics of erythromycin stinoprate capsule. Zhong Nan da Xue Xue Bao. Yi Xue Ban 30(2): 197-201

Wren, B.G.; Day, R.O.; McLachlan, A.J.; Williams, K.M. 2003: Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women. Climacteric: the Journal of the International Menopause Society 6(2): 104-111

Anderson, G.D.; Odegard, P.S. 2004: Pharmacokinetics of estrogen and progesterone in chronic kidney disease. Advances in Chronic Kidney Disease 11(4): 357-360

Zhu, M.; Burman, W.J.; Starke, J.R.; Stambaugh, J.J.; Steiner, P.; Bulpitt, A.E.; Ashkin, D.; Auclair, B.; Berning, S.E.; Jelliffe, R.W.; Jaresko, G.S.; Peloquin, C.A. 2004: Pharmacokinetics of ethambutol in children and adults with tuberculosis. International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 8(11): 1360-1367

Zhao, Q.; Janssens, L.; Verhaeghe, T.; Brashear, H.R.; Truyen, L. 2005: Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Current Medical Research and Opinion 21(10): 1547-1554

Morfini, M. 2003: Pharmacokinetics of factor VIIi and factor IX. Haemophilia: the Official Journal of the World Federation of Hemophilia 9(Suppl 1): 94-99; Discussion 100

Wenning, L.A.; Murphy, M.G.; James, L.P.; Blumer, J.L.; Marshall, J.D.; Baier, J.; Scheimann, A.O.; Panebianco, D.L.; Zhong, L.; Eisenhandler, R.; Yeh, K.C.; Kearns, G.L. 2005: Pharmacokinetics of famotidine in infants. Clinical Pharmacokinetics 44(4): 395-406

Orsini, J.A.; Moate, P.J.; Kuersten, K.; Soma, L.R.; Boston, R.C. 2006: Pharmacokinetics of fentanyl delivered transdermally in healthy adult horses--variability among horses and its clinical implications. Journal of Veterinary Pharmacology and Therapeutics 29(6): 539-546

Verbist, L.; Van Hecken, A.; De Schepper, P. 1989: Pharmacokinetics of fleroxacin determined by biological method. Journal of ChemoTherapy 1(4 Suppl): 572-573

Aoyama, T.; Ogata, K.; Shimizu, M.; Hatta, S.; Masuhara, K.; Shima, Y.; Kimura, K.; Matsumoto, Y. 2005: Pharmacokinetics of fluconazole and fosfluconazole after intraperitoneal administration to peritoneal dialysis rats. Drug Metabolism and Pharmacokinetics 20(6): 485-490